

Index of subjects Volume 9 (1998)

A

ABMT

in patients with Hodgkin's disease 289

9-AC

in advanced non-small-cell lung cancer 1085

aclarubicin

for the treatment of acute myeloid leukemia (Short report) 221

acute myeloid leukemia

autologous peripheral blood progenitor 151

AVA for the treatment in elderly patients (Short report) 221

expression of *bcl-2* mRNA as a determinant of prognosis 159

resistance to chemotherapy (Editorial) 129

adaptation

of advanced stage Hodgkin's disease and acute leukemia survivors 297

adjustment

psychosocial adaptation of Hodgkin's disease 297

adjuvant

chemotherapy added to radiotherapy or tamoxifen (Commentary) 489

G-CSF (filgrastim)-supported FEC polychemotherapy in breast cancer patients 403

paclitaxel used for the treatment of breast cancer (Commentary) 973

advanced

breast cancer

randomised trial using letrozole and aminoglutethimide 639

colorectal carcinoma treated with

oxaliplatin (Short report) 105

leucovorin and fluorouracil 727

leucovorin, 5-fluorouracil and oxaliplatin (Short report) 1251

head and neck cancer

phase II trial of cisplatin and gemcitabine (Short report) 1347

stages in the treatment of Hodgkin's disease 195

aggressive lymphomas

alternating triple therapy for the treatment of 511

conditioning regimens before transplantation (Review) S1: 15

aggressive non-Hodgkin's lymphoma

high-dose therapy followed by stem cell transportation in partial response after first-line induction therapy (Review) S1: 5

AIDS

treatment of a related non-Hodgkin's lymphoma with chemotherapy (CNOP) and r-hu-G-CSF (Short report) 1135

alcohol-related pain

as a rare syndrome in Hodgkin's disease S5: 109

allograft

in adult lymphoblastic lymphoma 619

alpha-fetoprotein

and clinical use (Clinical case) 667

and its hereditary persistence (Clinical case) 667

alternating combination

of irinotecan with bolus 5-fluorouracil and leucovorin in first-line chemotherapy for metastatic colorectal cancer 1199

alternating triple therapy (ATT)

for the treatment of intermediate grade and immunoblastic lymphoma 511

amifostine

in concurrent radiotherapy for head and neck cancer 505

AML, see: acute myeloid leukemia

anecdotes

in evidence-based health care (Review on evidence-based cancer medicine) 963

anemia

as a rare syndrome in Hodgkin's disease S5: 109

frequency and significance in non-Hodgkin's lymphoma patients 1109

induced by chemotherapy as a side effect and its treatment with rhEPO 255

anthracycline

cardiotoxicity (Editorial) 691

cardiotoxicity in AIDS Kaposi's sarcoma patients 711

used in breast cancer patients (Letter to the editor) 461

used in elderly patients with non-Hodgkin's lymphoma 1219

anthroposophical medicine

as an addition to the assessment of quality of life for patients with advanced cancer 1091

antibiotic-associated diarrhea

in hospitalized oncology patients 307

antiemetics

results of the Perugia Consensus Conference (Special article) 811

treatment for cancer chemotherapy-induced nausea and vomiting 759

antiphospholipid syndrome

development of CD4 lymphocyte deficiency and non-Hodgkin's lymphoma (Letter to the editor) 921

antiretroviral therapy

in HIV-related Kaposi's sarcoma (Letter to the editor) 923

antitumor activity

in a melanoma model in mice 63

apoptosis

its role in the molecular genetics of cancer (Commentary) 23

aromatase inhibitors

for the treatment of postmenopausal women with advanced breast cancer 639

arrhythmia

and torsade de pointe in relation to the dose limiting toxicities of S9788 1233

arterial embolism

causing a primary osteosarcoma of the heart (Clinical case) 775

asbestos

and its relation to malignant mesothelioma (Review) 139

ascites

with respect to predominantly intraperitoneal malignancies 437

autograft

on patients with adult lymphoblastic lymphoma 619

autologous

hematopoietic stem-cell transplantation

for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (Short report) 1023

stem cell transplantation

for aggressive non-Hodgkin's lymphoma (Review) S1: 5, (Review) S1: 15

transplant

- for diffuse large-cell lymphoma in first remission (Review) S1: 9
- for diffuse large-cell non-Hodgkin's lymphoma (Review) S1: 1
- in bone marrow 289
- in primary refractory Hodgkin's disease S5: 97
- mobilized with high-dose cytarabine in AML 151
- of patients with transformed follicular lymphoma 865

B

Barrett's oesophagus

- cancer treatment (Review) 951

BCH-4556

- against human tumor colony-forming units 885

bcl-2

- high expression mRNA in acute myeloid leukemia 159
- related to the treatment of Hodgkin's lymphomas S5: 125

B-cell

- classification of lymphomas S5: 25, 45
- lymphomas and autologous transplantation 51
- non-Hodgkin's lymphoma related to clinico-pathological characterization of HCV 495

B-DLCL

- rearrangements of *bcl-6*, *bcl-2*, *c-myc* and 6q deletion 55

bias

- in evidence-based health care (Review on evidence-based cancer medicine) 963

biliary tract cancer

- treatment with 5-fluorouracil continuous infusion with cisplatin 653

biochemical modulation

- in the chemotherapy treatment of advanced colorectal cancer 727

bleomycin

- as a treatment for patients with head and neck cancer (Short report) 225

blood cell transplant

- in diffuse large-cell lymphoma (Review) S1: 23

bone marrow

- aspirate of patients with small-cell lung cancer 181
- hematopoiesis induced by interleukin-12 63
- involvement by tumor cells in patients with small-cell lung cancer (Review) 247
- transplantation in patients with Hodgkin's disease 289

bone metastasis

- of the jaw (Clinical case) 559

bone scan

- as staging procedure in breast cancer patients (Arena) 1173

bone scintigraphy

- of a osteosarcoma patient with late peritoneal metastasis (Clinical case) 907

bowel lymphoma

- in a patient with intestinal lymphangiectasia and viral warts (Letter to the editor) 1355

brachytherapy

- and external beam irradiation for localized prostate cancer 751

brain

edema

- human corticotropin-releasing factor 71

neoplasms

- treatment of malignant glioma with chemotherapy (Review) 589

BRCA1

- germline mutations linked to hereditary breast and ovarian cancer (Special article) 939

BRCA2

- germline mutations linked to hereditary breast and ovarian cancer (Special article) 939

breast cancer

- abdominal pain with anorexia (Clinical case) 1243
- activity of multidrug resistance gene product 85
- assessment of response in primary chemotherapy (Letter to the editor) 1140
- CD44v6 expression as a prognostic factor (Short report) 109
- clinical course of patients with metastases confined to the lungs 413
- CMF chemotherapy added to radiotherapy or tamoxifen (Commentary) 489
- detection by ¹¹¹In-pentetreotide scan (Clinical case) 213
- dose-intensity of anthracyclines (Letter to the editor) 461
- growth stimulation in the presence of tamoxifen 205
- hematopoietic progenitor cell collection and neoplastic cell contamination in patients receiving G-CSF and chemotherapy (Short report) 913
- levels of haematological toxicity 403
- minimal residual disease in autologous hematopoietic harvests (Review) 821
- neoadjuvant chemoendocrine therapy 1179
- new treatments in patient care (Commentary) 973
- occurrence of *Pneumocystis carinii* pneumonia (Letter to the editor) 573
- paclitaxel combined with 5-fluorouracil and leucovorin as treatment 45
- primary chemotherapy as therapeutic option for patients with breast cancer (Editorial) 1151
- quality of life assessment in patients receiving adjuvant therapy (Letter to the editor) 231
- recommendations for medical management (Special article) 939
- staging procedures in clinical or research settings (Arena) 1173
- the changing landscape of clinical research (Special article) 133
- breast neoplasm
 - in patients with postmastectomy lymphedema 187
- Burkitt's lymphoma
 - in a patient with Denys-Drash syndrome 627
 - related to the Epstein-Barr virus S5: 5

C**C2B8**

- used in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995

calcitonin

- plasma measurements in medullary thyroid carcinoma (Review) 695

cancer

- and the development of an isolated chylopericardium (Clinical case) 1339
- and overdiagnosis by screening (Debate) 1297
- care
 - the impact of specialization on the processes and outcomes (Review) 365
- cost-effectiveness analysis (Review) 475

- pain
- equianalgesic dose/ratio between methadone and other opioid agonists 79
 - somastostatin in association with morphine in advanced cancer patients (Letter to the editor) 921
 - recent advances in the molecular genetics (Commentary) 23
 - registry of patients with small-cell lung cancer 543
 - research (Special article) 251
 - risk management without adequate data (Editorial) 929
 - survivors and psychosocial adaptation of advanced stage Hodgkin's disease 297
 - vaccine of hr-EGF linked to a carrier protein 431
- carboplatin
- compared to cisplatin in solid tumors (Review) 13
 - efficacy and safety in combination with paclitaxel in patients with ovarian carcinoma 37
 - toxic effects on the peripheral nervous system of the rat 443
- carcinoma *in situ*
- of the testis and the effect of chemotherapy 657
- cardiac osteosarcoma
- as a cause of recurrent peripheral arterial emboli (Clinical case) 775
- cardiotoxicity
- in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin 711
 - of anthracycline (Editorial) 691
- case-control study
- of surviving prostate cancer patients 751
- CD20 monoclonal antibody
- in relapsed B-cell lymphoma 527
- CD34+ HPC's
- for autologous transplantation in B-cell non-Hodgkin's lymphomas 51
- CD4 lymphocyte deficiency
- and non-Hodgkin's lymphoma in the antiphospholipid syndrome (Letter to the editor) 921
- CD44v6
- as prognostic factor in primary breast cancer (Short report) 109
- cell lines
- comparison of toxicity of different schedules of ET-743 989
- central nervous system disease
- using prophylaxis in patients with aggressive non-Hodgkin's lymphoma 191
- central venous catheters
- for long-term chemotherapy 767
- certification
- and training for medical oncology through the ESMO programme (Special article) 585
- cervical cancer
- neoadjuvant chemotherapy with cisplatin, ifosfamide and paclitaxel 977
 - with a rib metastasis in an adult (Clinical case) 1015
- cervix carcinoma
- the role of chemotherapy treatment (Editorial) 933
- CFU-GM
- in cytotoxic drug therapy (Special article) 357
- chemokine
- in immune escape mechanisms in Hodgkin's disease S5: 21
- chemoradiotherapy
- for head and neck cancer (Editorial) 471
- chemotherapy
- and bone marrow transplantation in adult lymphoblastic lymphoma 619
 - and radiotherapy-induced emesis 811
 - and r-hu-G-CSF as treatment for AIDS-related non-Hodgkin's lymphoma (Short report) 1135
 - and surgery for osteosarcoma of the limbs 893
 - central venous access ports for long-term treatment 767
 - in early stage Hodgkin's disease S5: 57, 63
 - on patients with
 - acute myeloid leukemia (Editorial) 129
 - adult lymphoblastic lymphoma 619
 - advanced biliary tract carcinoma 653
 - advanced carcinoma of the cervix (Editorial) 933
 - advanced Hodgkin's disease S5: 67, 73
 - advanced non-small-cell lung cancer (Short report) 677
 - breast cancer (Letter to the editor) 1140
 - carcinoma *in situ* of the testis 657
 - chronic lymphocytic leukemia (Editorial) 131
 - colorectal cancer liver metastasis (Arena) 967
 - HBV (Letter to the editor) 117
 - high-grade non-Hodgkin's lymphoma 1213
 - high-risk breast cancer patients 403
 - Hodgkin's disease 289, S5: 57, 63, 103
 - large cell B-cell non-Hodgkin's lymphoma (Rapid publication) 385
 - malignant glioma (Review) 589
 - malignant mesothelioma 269
 - malignant pleural mesothelioma (Review) 139
 - metastases confined to the lungs 413
 - non-small-cell lung cancer (Short report) 331, (Short report) 457, 1079
 - ovarian carcinoma 37
 - post-transplant lymphoproliferative disease (Letter to the editor) 339
 - primary breast cancer 1179
 - primary cervical malignant teratoma with a rib metastasis (Clinical case) 1015
 - primary extranodal lymphomas of the ocular adnexa (Short report) 779
 - primary mediastinal large B-cell lymphoma with sclerosis (Short report) 1027
 - testicular teratoma (Letter to the editor) 118
 - chemotherapy-induced
 - anemia associated with solid tumors 255
 - emesis antiemeticly prophylactically treated 759
 - peripheral neuropathy 739
 - chemotherapy-radiotherapy combination S5: 57
 - chest radiography
 - as staging procedure for breast cancer patients (Arena) 1173
 - chimeric IDEC-C2B8
 - in relapsed B-cell lymphoma 527
 - 2-chlorodeoxyadenosine
 - inducing toxicity in pretreated lymphocytic leukaemia 721
 - CHOP
 - and the treatment for intermediate grade lymphomas 511
 - in untreated patients with high-grade non-Hodgkin's lymphoma 1213
 - CHOP-Mtx vs. CAPOMeT

- in the treatment of aggressive non-Hodgkin's lymphoma 633
- chronic
 - lymphocytic leukemia 167
 - high incidence of relapse after autologous stem-cell transplantation (Short report) 1023
 - treatment with cladribine 721
 - myeloid leukemia (Editorial) 351, 389
- chylopericardium
 - of neoplastic aetiology (Clinical case) 1339
- cisplatin
 - chemistry followed by granisetron plus dexamethasone in controlling delayed nausea and vomiting 661
 - chemistry followed by surgery for osteosarcoma of the limbs 893
 - combined with docetaxel as a first-line treatment of advanced non-small-cell lung cancer (Short report) 331
 - combined with gemcitabine in advanced squamous-cell carcinoma of the head and neck (Short report) 1347
 - combined with paclitaxel in patients with recurrent squamous cell carcinoma of the head and neck (Short report) 335
 - compared to carboplatin in solid tumors (Review) 13
 - resistant cell lines in ovarian cancer 423
- cladribine
 - inducing toxicity in pretreated chronic lymphocytic leukaemia 721
- classification
 - of lymphoma entities (Commentary) 607, S5: 45
 - of Sézary syndrome 857
- Clinical cases
 - alpha-fetoprotein
 - and clinical use 667
 - and its hereditary persistence 667
 - arterial embolism
 - causing a primary osteosarcoma of the heart 775
 - bone metastasis
 - of the jaw 559
 - bone scintigraphy
 - of an osteosarcoma patient with late peritoneal metastasis 907
 - breast cancer
 - abdominal pain with anorexia 1243
 - detection by ¹¹¹In-pentetreotide scan 213
 - cancer
 - and the development of an isolated chylopericardium 1339
 - cardiac osteosarcoma
 - as a cause of recurrent peripheral arterial emboli 775
 - cervical cancer
 - with a rib metastasis in an adult 1015
 - chemotherapy
 - on patients with
 - primary cervical malignant teratoma with a rib metastasis 1015
 - chylopericardium
 - of neoplastic aetiology 1339
- CT scan
 - documenting thymic and mediastinal lymph node enlargements 95
- diagnosis
 - of patients with unknown primary carcinoma 213
- fever of unknown origin (FUO)
 - caused by psoriasiform lesions as paraneoplastic manifestation in Hodgkin's disease 449
- follow-up
 - of patients with osteosarcoma 907
- galliumscintigraphy
 - for diagnosis of thymic hyperplasia 95
- gastrointestinal metastases
 - after malignant melanoma in breast cancer patients 1243
- germ cell
 - tumors
 - and sarcoidosis 321
 - in analogy to the prognosis of malignant teratoma 1015
- hematotoxicity
 - of tamoxifen in patients with a liver disease 1123
- hereditary persistence
 - of alpha-fetoprotein 667
- Hodgkin's disease
 - psoriasiform lesions as paraneoplastic manifestation 449
- invasive lobular carcinoma
 - as predominant histological subtype of gastrointestinal metastases of breast cancer 1243
- lymphoma
 - primary therapy for 95
- mandible
 - pain as the leading clinical symptom for metastatic disease 559
- metastatic breast cancer
 - detection by ¹¹¹In-pentetreotide scan 213
- monitoring
 - hepatic dysfunction in liver disease by tamoxifen 1123
- neoplasia
 - and the treatment of chylopericardium 1339
- nodular sclerosis
 - as a manifestation in Hodgkin's disease 449
- nuclear medicine
 - for primary breast cancer presenting as metastatic carcinoma of unknown primary origin 213
- numb lip syndrome
 - as a sign for metastatic disease (Clinical disease) 559
- osteosarcoma
 - late peritoneal metastasis in a patient 907
- paraneoplastic lesions
 - as paraneoplastic manifestation in Hodgkin's disease 449
- pericardial effusion
 - of chylous fluid in chylopericardium 1339
- peritoneal metastasis
 - in a patient with osteosarcoma 907
- physiopathology
 - of a patient with osteosarcoma having late peritoneal metastasis 907
- prognosis
 - in primary cervical malignant teratoma 1015
- psoriasiform lesions
 - in Hodgkin's disease 449
- residual mass
 - after primary therapy for lymphoma 95
- sarcoidosis
 - coincidence of seminoma 321
- seminoma
 - coincidence of sarcoidosis 321
- skin lesions
 - in Hodgkin's disease 449

- surgery
 - of patients with primary cervical malignant teratoma with a rib metastasis 1015
- tamoxifen
 - in liver disease as potential exacerbation of hepatic dysfunction 1123
- teratoma
 - with a rib metastasis in an adult 1015
- TIPS
 - treatment for patients with a liver disease 1123
- transesophageal echocardiography
 - performance in patients with symptoms of systemic arterial embolism 775
- tumor markers
 - the role of alpha-fetoprotein (AFP) 667
- clinical
 - correlations
 - of *bcl-6*, *bcl-2*, *c-myc* rearrangements and 6(q) deletions in B-DLCL 55
 - features
 - impact of hepatitis C virus 499
 - phase II study
 - of new drugs in the treatment of Hodgkin's disease S5: 103
 - guidelines
 - and documented clinical policies (Review on evidence-based cancer medicine) 1073
 - oncology
 - and PET scanning (Editorial) 353
 - research
 - of breast cancer (Special article) 133
 - significance
 - related to the quality of life in patients with Hodgkin's lymphoma S5: 137
 - trials (Special article) 251
 - for the treatment of adult Hodgkin's disease S5: 79
 - in the quality of life assessment in Hodgkin's disease S5: 147
- clofazimine
 - in hepatocellular carcinoma (Short report) 217
- clonality
 - of Hodgkin-Reed Sternberg specific immunoglobulin gene rearrangements 283
- cloning assay
 - used for determining *in vitro* effects of ET-743 against primary human tumor specimens 981
 - used for evaluating antitumor activity of BCH-4556 885
- Clostridium difficile* diarrhea
 - determination and validation of a predictive model in hospitalized oncology patients 307
- CMF
 - chemotherapy added to radiotherapy or tamoxifen (Commentary) 489
- CNS involvement
 - as a rare syndrome in Hodgkin's disease S5: 109
- coagulation
 - prognostic impact of an activation in lung cancer (Letter to the editor) 1255
- cognition
 - in the use of anecdotal information in evidence-based health care (Review on evidence-based cancer medicine) 963
- cognitive-spiritual quality of life
 - as important assessment for patients with advanced cancer 1091
- colon adenocarcinoma
 - and the use of Irinotecan (Short report) 453
- colorectal cancer
 - addition of low-dose leucovorin to monthly 5-fluorouracil 535
 - clinical and preclinical use of oxaliplatin (Review) 1053
 - 5-fluorouracil and mitomycin-C (Letter to the editor) 230
 - liver metastasis and local treatment (Arena) 967
 - prevention with a screening model employing sigmoidoscopy 613
 - screening (Editorial) 581
 - topotecan with granulocyte-colony stimulating factor 173
 - with special biological features 901
- colorectal neoplasms
 - local treatment for colorectal cancer liver metastasis (Arena) 967
- combined modality therapy in patients with
 - carcinoma of the esophagus 647
 - Hodgkin's disease in early stage S5: 63
 - Hodgkin's disease at advanced stages 195
 - pediatric Hodgkin's disease (Review) S5: 115
 - surgically staged IIIA-N2 non-small-cell lung cancer 261, 1193
- communication
 - in clinical cancer research (Special article) 251
 - in evidence-based health care (Review on evidence-based cancer medicine) 963
- concentration-controlled
 - randomised comparison of standard vs. prolonged infusions of etoposide phosphate in small-cell lung cancer 1205
- concomitant chemoradiotherapy
 - for carcinoma of the esophagus 647
- concurrent chemo- and radiation therapy
 - for head and neck cancer 505
- conditioning regimen
 - before transplantation in patients with aggressive non-Hodgkin's lymphoma (Review) S1: 15
- conduct
 - facilitated by improving quality of trial reports (Review on evidence-based cancer medicine) 483
- conservative surgery
 - in stage I of ovarian carcinoma 1097
- continuing education
 - in the field of cancer medicine (Review on evidence-based cancer medicine) 377
- continuous infusion
 - with fluorouracil in the treatment of advanced colorectal cancer 727
- corticotropin-releasing factor
 - in patients with peritumoral brain edema 71
- cost analysis
 - in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167
- cost-effectiveness
 - analysis
 - in oncology (Review) 475
 - of clinical studies 389
 - approach to prevent colorectal cancer 613
 - of interferon-alpha (Editorial) 351
- CPT-11
 - with bolus 5-fluorouracil and leucovorin in first-line chemotherapy for metastatic colorectal cancer 1199

- cross cultural comparison
 - of the quality of life assessment in the treatment of early breast cancer 745
- CT scan
 - documenting thymic and mediastinal lymph node enlargements (Clinical case) 95
- cutaneous T-cell lymphoma
 - in Sézary syndrome 857
- cytarabine
 - in acute myeloid leukemia mobilizing autologous peripheral blood progenitor cell transplantation 151
- cytogenetics
 - for the detection of t(11;14)(q13;q32) in mantle cell lymphomas 519
- cytosine arabinoside
 - for the treatment of acute myeloid leukemia (Short report) 221
- cytotoxic T lymphocyte (CTL)
 - in the treatment of relapsed Hodgkin's disease S5: 129
 - response in control of an Epstein-Barr virus infection S5: 5
- D**
 - data interpretation
 - its role in evidence-based health care in relation to anecdotes (Review on evidence-based cancer medicine) 963
 - decision making
 - in relation to anecdotal information in evidence-based health care (Review on evidence-based cancer medicine) 963
 - delayed emesis
 - controlled with granisetron plus dexamethasone or dexamethasone alone 661
 - dendritic cell
 - in the treatment of relapsed Hodgkin's disease S5: 129
 - Denys-Drash syndrome
 - WT1 involvement in a Burkitt's lymphoma 627
 - Dexa-BEAM regimen
 - in the treatment of patients with relapsed or refractory Hodgkin's disease 289
 - dexamethasone
 - in controlling delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy 661
 - diagnosis
 - of patients with unknown primary carcinoma (Clinical case) 213
 - of prostate carcinoma by screening (Debate) 1297
 - diaminocyclohexane
 - for the treatment of advanced colorectal cancers (Review) 1053
 - diarrhea in cancer patients
 - determination and validation of a predictive model 307
 - differential diagnosis
 - of Hodgkin's lymphoma and related diseases S5: 31
 - diffuse large-cell lymphoma
 - high-dose therapy in first remission (Review) S1: 9
 - DMP 840
 - administered by 24-hour infusion (Short report) 101
 - docetaxel
 - and cisplatin as first-line treatment of advanced non-small-cell lung cancer (Short report) 331
 - and onycholysis in patients (Letter to the editor) 230
 - as substitution of paclitaxel (Letter to the editor) 573
 - dose escalation
 - in BEACOPP chemotherapy for advanced Hodgkin's disease S5: 67
 - dose intensification
 - in the treatment of adult Hodgkin's disease S5: 79
 - dose-intensity
 - of anthracyclines in breast cancer (Letter to the editor) 461
 - dose response relationship
 - in patients with Hodgkin's disease receiving BEACOPP regimen S5: 73
 - doxorubicin
 - in the treatment of adult patients with soft tissue sarcoma (Short report) 783, (Short report) 917
 - in the treatment of patients with a lack of activity in poor prognosis soft tissue sarcomas (Short report) 1131
 - development in clinical cancer research (Special article) 251
 - for patients with advanced non-small-cell lung cancer (Short report) 457
 - utilization for cancer chemotherapy-induced nausea and vomiting 759
 - drug-dependent platelet antibody
 - in the presence of Irinotecan (Short report) 453
- E**
 - early breast cancer
 - treatment with CMF and Zoladex (Goserlin) 745
 - early stages
 - of Hodgkin's disease S5: 63
 - EBV
 - positive Hodgkin's lymphoma S5: 45
 - EBV-associated lymphoproliferative disease (EBV-LPD)
 - and the treatment of relapsed Hodgkin's disease S5: 129
 - economic evaluation
 - in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167
 - ecteinascinscidins
 - against human tumors explanted from patients 981
 - in vitro schedule-dependency of myelotoxicity and cytotoxicity 989
 - education
 - in relation to evidence-based health care (Review on evidence-based cancer medicine) 963
 - effectiveness
 - of antiemetic drugs in patients undergoing cancer chemotherapy 759
 - efficacy
 - of BEACOPP chemotherapy for advanced Hodgkin's disease S5: 67
 - elderly patients
 - with acute myeloid leukemia (Short report) 221
 - with non-Hodgkin's lymphoma 1219
 - emission computed tomography
 - after induction chemotherapy in non-small-cell lung cancer 1193
 - endomyocardial biopsy
 - to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients 711
 - endpoint
 - for evaluating new cytotoxic agents in phase II trials of non-small-cell lung cancer 1079
 - EORTC QLQ-C30
 - evaluation of the questionnaire and long-survival cancer patients 549
 - epidemiology
 - of patients with malignant pleural mesothelioma (Review) 139

- of Hodgkin's lymphoma S5: 45
- of the non-Hodgkin's lymphomas 717
- of vulvar and vaginal cancers 1229
- epidermal growth factor
 - in relation to the antineoplastic activity of suramin in patients with breast cancer 205
 - linked to a carrier protein as a novel cancer vaccine 431
- epithelial tumor cells
 - detection in blood or bone marrow (Review) 1269
- Epstein-Barr virus
 - in Hodgkin's lymphoma S5: 5
 - in relapsed Hodgkin's disease S5: 129
- equianalgesia
 - in cancer pain treatment 79
- erythropoietin
 - in patients with solid tumours (Editorial) 239
 - in the prevention of transfusion requirement 255
 - in the treatment of chemotherapy-induced anemia 255
- ESMO-MORA
 - programme of certification and training for medical oncology (Special article) 585
- esophageal carcinoma
 - a long-term analysis of a combined modality therapy 647
- etoposide
 - addition to CHOP chemotherapy in patients with non-Hodgkin's lymphoma 1213
 - for the treatment of acute myeloid leukemia (Short report) 221
 - for the treatment of small-cell lung cancer 1205
- evidence
 - in reducing mortality from prostate cancer due to PSA screening (Debate) 1293
- evidence-based medicine (Review on evidence-based cancer medicine) 377, 703, 963
- Ewing tumor
 - Survival analysis of patients from the EICES studies 275
- extended field radiation
 - in the treatment of Hodgkin's disease S5: 79
- extranodal lymphomas
 - treatment and prognosis in the ocular adnexa (Short report) 779
 - workshop on peripheral T-cell lymphomas (Commentary) 835
- F**
- famciclovir
 - in the treatment of patients with high-grade non-Hodgkin's lymphoma (Rapid publication) 385
- FAS
 - in Hodgkin's disease immune escape mechanisms S5: 21
- FASL
 - in Hodgkin's disease immune escape mechanisms S5: 21
- fatigue
 - and the impact on quality of life of Hodgkin's lymphoma survivors S5: 137
- FDG-PET
 - for accurate staging of Hodgkin's disease 1117
- feasibility study
 - of a chimeric anti-CD20 monoclonal antibody in relapsed B-cell lymphoma 527
- fes/fps
 - oncogene related to the treatment of Hodgkin's lymphomas S5: 125
- fever of unknown origin (FUO)
 - caused by psoriasiform lesions as paraneoplastic manifestation in Hodgkin's disease (Clinical case) 449
- F-fluorodeoxyglucose (FDG)
 - PET in the detection of liver metastases 397
- first-line chemotherapy
 - of metastatic colorectal cancer 1199
- first remission
 - of Hodgkin's disease patients S5: 83
- fluorescence *in situ* hybridization
 - for the detection of the t(11;14) region in mantle cell lymphomas 519
- fluorouracil
 - used for the treatment of advanced colorectal carcinoma 535, 727
- 5-fluorouracil
 - biochemical modulation in patients with advanced colorectal cancer 1309
 - used in combination with leucovorin and oxaliplatin in the treatment of metastatic colorectal cancer (Short report) 1251
- follicular lymphoma
 - for the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995
 - histologic transformation (Editorial) 803
- follow-up
 - of patients with osteosarcoma (Clinical case) 907
- Frey's syndrome
 - after cisplatin-based chemotherapy for testicular teratoma (Letter to the editor) 118
- G**
- G-CSF (filgrastim)
 - supported FEC polychemotherapy in high-risk breast cancer patients 403
 - used for mobilization in breast cancer patients (Short report) 913
 - with CNOP in the treatment of AIDS-related non-Hodgkin's lymphoma (Short report) 1135
- galliumscintigraphy
 - for diagnosis of thymic hyperplasia (Clinical case) 95
- gastrointestinal metastases
 - after malignant melanoma in breast cancer patients (Clinical case) 1243
- gemcitabine
 - causing hemolytic-uremic syndrome (Letter to the editor) 1355
 - combined with cisplatin regimen for patients with non-small-cell lung cancer (Short report) 457
 - combined with paclitaxel in patients with refractory solid tumors 733
 - for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy (Short report) 1127
 - in patients with solid tumors 1003
 - in platinum pre-treated patients with advanced epithelial cancer 1343
 - in pretreated peripheral T-cell lymphoma patients (Short report) 1351
 - in the treatment of Hodgkin's disease S5: 103
 - inducing veno-occlusive disease of the liver (Letter to the editor) 681
- gene-marking
 - in relapsed Hodgkin's disease patients S5: 129
- gene therapy
 - for malignant glioma (Review) 589, (Review) 1155

- gene transfer
 - in relapsed Hodgkin's disease patients S5: 129
- genetic
 - lesions in B-diffuse large-cell lymphoma 55
 - polymorphism in a promoter region of *UGT1A1* (Rapid publication) 845
- geography
 - in the distributions of the major subtypes in the epidemiology of non-Hodgkin's lymphoma's 717
- germ cell
 - cancer
 - treatment after failed high-dose therapy (Letter to the editor) 787
 - tumors
 - and sarcoidosis (Clinical case) 321
 - in analogy to the prognosis of malignant teratoma (Clinical case) 1015
- glioma
 - treatment with chemotherapy or experimental methods (Review) 589
- glucuronidation
 - of SN-38, the active metabolite of irinotecan (Rapid publication) 845
- gonadal dysfunction after chemotherapy
 - in pediatric Hodgkin's disease (Review) S5: 115
- grading
 - severity of chemotherapy-induced peripheral neuropathy 739
- graft-versus-lymphoma
 - effects in the treatment of lymphoma (Review) S1: 31
- granisetron
 - plus dexamethasone in delaying nausea and vomiting in patients receiving emetogenic chemotherapy 661
- granulocyte colony-stimulating factor
 - in a melanoma model in mice 63
 - in fluoropyrimidine-refractory colorectal cancer 173
- grey zone
 - between classical Hodgkin's lymphoma and non-Hodgkin's lymphoma S5: 31
- grey zone lymphoma
 - treatment of (Review) S5: 121
- Groshong catheter
 - used for long-term chemotherapy 767
- growth
 - factors in ascites of ovarian cancer patients 437
 - stimulation in the presence of tamoxifen 205
- guidance
 - of service, other guidelines and documented clinical policies (Review on evidence-based cancer medicine) 1073
- guideline development
 - and documented clinical policies (Review on evidence-based cancer medicine) 1073
- gynecological sarcomas
 - treatment with combined high-dose ifosfamide and doxorubicin 877
- H**
- hCRF
 - in patients with peritumoral brain edema 71
- HCV
 - and lymphoproliferative diseases (Editorial) 469
- head and neck cancer
 - an EORTC-ECSCG phase II study of vinorelbine 1103
 - paclitaxel in combination with cisplatin as a treatment (Short report) 335
 - selective cytoprotection with amifostine in concurrent radiochemotherapy 505
 - the therapeutic index of concomitant chemoradiotherapy (Editorial) 471
 - vinorelbine, bleomycin and methotrexate as a salvage therapy (Short report) 225
- health
 - economics
 - cost-effectiveness analysis (Review) 475
 - cost-effectiveness approach for the prevention of colorectal cancer 613
 - outcome assessment
 - in a cohort of Italian long-survival cancer patients 549
- health-related quality of life
 - in patients with Hodgkin's lymphoma S5: 137
 - in patients with long-survival cancer patients 549
- hematopoietic stem cell transplantation
 - in chronic lymphocytic leukemia 167
- hematotoxicity
 - of a cytotoxic drug (Special article) 357
 - of tamoxifen in patients with a liver disease (Clinical case) 1123
- hematotoxicology
 - in relation to Ecteinascidin (ET-743) 989
- hemolytic-uremic syndrome
 - caused by gemcitabine (Letter to the editor) 1355
- hepatitis
 - B virus infection following intensive therapy for high-grade non-Hodgkin's lymphoma (Rapid publication) 385
- C virus
 - impact of infection on patients with lymphoplasmacytoid lymphoma/immunocytoma 499
 - related to B-cell non-Hodgkin's lymphomas 495
 - prevention of development (Letter to the editor) 117
- hepatocellular carcinoma
 - treated with oral clofazimine (Short report) 217
- Herceptin[®]
 - in new treatments for breast cancer (Commentary) 973
- hereditary persistence
 - of alpha-fetoprotein (Clinical case) 667
- heterozygosity
 - loss in patients with non-small-cell lung cancer patients (Short report) 113
- high-dose
 - chemotherapy on patients with
 - aggressive non-Hodgkin's lymphoma (Review) S1: 15
 - breast cancer (Review) 821
 - Hodgkin's disease S5: 87
 - relapsed or refractory Hodgkin's disease 289
 - doxorubicin
 - in the treatment of advanced sarcomas 877
 - ifosfamide
 - for soft tissue sarcomas (Editorial) 907
 - in adult patients with advanced soft tissue sarcoma (Short report) 783
 - in advanced soft tissue sarcomas of the adult 871

- in the treatment of advanced sarcomas 877
- plus adriamycin in the treatment of adult advanced soft tissue sarcomas (Short report) 917
- therapy
 - for aggressive non-Hodgkin's lymphoma (Review) S1: 5
 - for diffuse large-cell lymphoma in first remission (Review) S1: 9
- high-grade non-Hodgkin's lymphoma
 - addition of etoposide to CHOP chemotherapy in untreated patients 1213
- histologic
 - subtypes
 - in the epidemiology of the non-Hodgkin's lymphomas 717
 - transformation in follicular lymphoma (Editorial) 803
- histological type
 - and microsatellite instability of HNPCC families 901
- histopathology
 - of lymphocyte predominance Hodgkin's disease S5: 39
- HIV-1 viral replication
 - treatment for non-Hodgkin's lymphoma (Short report) 1135
- Hodgkin's disease
 - accurate staging with FDG-PET 1117
 - appearance of thymic mass after therapy for lymphoma 95
 - BEACOPP chemotherapy as new regimen S5: 67
 - classification of lymphoma entities (Commentary) 607, S5: 25
 - clonality and germinal centre B-cell derivation of Hodgkin/Reed-Sternberg cells S5: 17
 - comparison of psychological adaptation 297
 - current clinical trials for treatment of adult patients S5: 79
 - direction of identical Hodgkin-Reed Sternberg cell specific immunoglobulin rearrangements 283
 - high-dose therapy with stem cell rescue in first remission S5: 83
 - immune escape mechanisms S5: 21
 - in relation to the Epstein-Barr virus S5: 5
 - long term toxicity of the treatment S5: 133
 - lymphocyte predominance S5: 39
 - new drugs in the treatment S5: 103
 - occurring in a child after liver transplantation (Short report) 673
 - psoriasiform lesions as paraneoplastic manifestation (Clinical case) 449
 - quality of life assessment S5: 147
 - pathology S5: 45
 - primary refractory S5: 97
 - radiation therapy as a component of high dose salvage strategies S5: 87
 - radiotherapy in early stage S5: 57, 63
 - rare syndromes S5: 109
 - role of moderate dose escalation in a randomised trial S5: 73
 - salvage therapy S5: 87
 - survivors and the quality of life S5: 137
 - treatment of grey zone lymphomas (Review) S5: 121
 - treatment of the relapse S5: 91, 129
 - treatment with
 - high-dose chemotherapy and stem cell rescue 289
 - three cycles of ABVD and high-dose extended irradiation 195
 - workshop report on 'grey zone' lymphoma S5: 31
- 5-HT₃ antagonists
 - in the management of cancer chemotherapy-induced nausea and vomiting 759
 - in the prevention of chemotherapy- and radiotherapy-induced emesis (Special article) 811
- 5-HT₃-receptor antagonist
 - in the management of delayed nausea and vomiting in patients receiving highly emetogenic chemotherapy 661
- hydromorphone
 - methadone as an alternative for treating cancer pain 79
- I**
- IDEC**
 - in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995
- ifosfamide
 - in patients with anthracycline-resistant metastatic breast cancer (Short report) 565
 - in patients with osteosarcoma of the limbs 893
- Ig gene rearrangements
 - in Hodgkin's disease S5: 17
- IL-10
 - in Hodgkin's disease immune escape mechanisms S5: 21
- immune thrombocytopenia
 - after treatment with Irinotecan (Short report) 453
- immunocytochemistry
 - used in the detection of contaminating epithelial tumor cells (Review) 1269
- immunoglobulin gene rearrangements
 - in patients with Hodgkin's disease 283
- immunohistochemistry
 - and the distinction between Hodgkin's disease and related diseases S5: 31
 - in a case of Hodgkin's disease occurring in a child after liver transplantation (Short report) 673
- immunology
 - of Sézary syndrome 857
- immunomagnetic purging
 - of peripheral blood CD34+ cells 51
- immunophenotype
 - of various Hodgkin's lymphomas S5: 45
- immunotherapy
 - for patients with Hodgkin's disease S5: 5, 103, 129
 - for patients with malignant glioma (Review) 589
 - for patients with recurrent low-grade or follicular non-Hodgkin's lymphoma 995
 - in conjunction with autologous and allogeneic blood or marrow transplantation in lymphoma (Review) S1: 31
- incidence
 - from prostate cancer 31
 - of second neoplasms following vaginal and vulvar cancers 1229
- individual patient data
 - systematic reviews (Review on evidence-based cancer medicine) 827
- individualized chemotherapy
 - in high-risk breast cancer patients 403
- induced tumours
 - as a result of late radiation in patients with early stage Hodgkin's disease S5: 63
- induction chemotherapy
 - for carcinoma of the esophagus 647
 - in non-small-cell lung cancer 261
- induction failure

- in primary refractory Hodgkin's disease S5: 97
- infection
 - as an effect of dose reduction of cladribine in pretreated chronic lymphocytic leukaemia 721
- information
 - retrieval in its role to solve clinical questions (Review on evidence-based cancer medicine) 377
 - technology in its role to solve clinical questions (Review on evidence-based cancer medicine) 377
- in situ* hybridization
 - in a case of Hodgkin's disease occurring in a child after liver transplantation (Short report) 673
- insulin-like growth factor-I
 - in human breast cancer cell lines after tamoxifen therapy 205
- interferon
 - in chronic myeloid leukemia 389
- interferon-alpha
 - for chronic myeloid leukemia (Editorial) 351
 - in HBV carriers (Letter to the editor) 117
 - in the treatment of patients with lymphoma (Review) S1: 31
- interleukin-2
 - in the treatment of patients with lymphoma (Review) S1: 31
- interleukin-12
 - in combination with GF-CSF preventing the suppression of bone marrow hematopoiesis 63
- intermediate grade lymphomas
 - alternating triple therapy for the treatment of 511
- international cooperation
 - in cancer research (Special article) 251
- Internet
 - its role in solving clinical questions (Review on evidence-based cancer medicine) 377
- intraarterial therapy
 - for osteosarcoma of the limbs 893
- in vitro* assays
 - schedule-dependency of myelotoxicity of Ecteinascidin 743 (ET-743) 989
- in vitro* tests
 - predicting hematological toxicity of cytotoxic drug therapy (Special article) 357
- invasive lobular carcinoma
 - as predominant histological subtype of gastrointestinal metastases of breast cancer (Clinical case) 1243
- Irinotecan
 - in first-line chemotherapy of metastatic colorectal cancer 1199
 - inducing immune thrombocytopenia (Short report) 453
 - metabolized by esterase to form SN-38 (Rapid publication) 845
- irradiation
 - for localized prostate cancer 751
- J**
- JAK**
 - related to the treatment of Hodgkin's lymphomas S5: 125
- K**
- Kaposi's sarcoma
 - highly active antiretroviral therapy (Letter to the editor) 923
 - patients treated with pegylated liposomal doxorubicin 711
- keeping up-to-date
 - of medical literature (Review on evidence-based cancer medicine) 377
- L**
- L-nucleoside analogue
 - activity against human tumor colony-forming units 885
- lamivudine
 - in the treatment for hepatitis B infection after therapy for non-Hodgkin's lymphoma (Rapid publication) 385
- late toxicity
 - after treatment of Hodgkin's disease S5: 63, 133
- latent membrane protein 2 (LMP2)
 - used in the treatment of patients with relapsed Hodgkin's disease S5: 129
- letrozole
 - and aminoglutethimide in postmenopausal women with advanced breast cancer 639
- leucovorin
 - in combination with 5-fluorouracil and oxaliplatin for metastatic colorectal cancer (Short report) 1251
- leukemia
 - classification published by the WHO S5: 25
 - survivors and their psychosocial adaptation 297
- life situation questionnaire (LSQ)
 - for analysing the quality of life of patients with Hodgkin's disease S5: 147
- limited stages
 - of Hodgkin's disease S5: 57
- liposomal doxorubicin
 - in poor prognosis soft tissue sarcomas (Short report) 1131
- liver
 - cancer
 - assessment of metastatic involvement 397
 - metastasis
 - detection with whole-body ¹⁸F-fluorodeoxyglucose positron emission tomography 397
 - local treatment in colorectal cancer patients (Arena) 967
 - transplantation
 - followed by Hodgkin's disease in a child (Short report) 673
 - ultrasonography
 - as staging procedure for breast cancer patients (Arena) 1173
 - veno-occlusive disease induced by gemcitabine (Letter to the editor) 681
- localized prostate cancer
 - treated with brachytherapy and external beam irradiation 751
- long QT
 - interval on ECG in patients with ventricular arrhythmia and torsade de pointe 1233
- long-survival cancer patients
 - comparison with SF-36 Health Survey 549
- low-dose
 - chemotherapy in the treatment of PTLD following solid organ transplantation (Letter to the editor) 339
 - leucovorin added to monthly 5-fluorouracil in advanced colorectal carcinoma 535
- low grade
 - non-Hodgkin's lymphoma and the treatment with Rituximab 995
- lung
 - metastases for germ-cell tumours 1185

- metastases in breast cancer 413
- surgery on patients treated with VIP induction chemotherapy 261
- lung cancer
 - activation of coagulation (Letter to the editor) 1255
 - and new cytotoxic agents 1079
- lymph node
 - in patients with stage I ovarian carcinoma 1097
- lymphatic metastasis
 - combined modality treatment for N₂ non-small-cell lung cancer 1193
- lymphoma
 - chimeric anti-CD20 monoclonal antibody in 527
 - classification published by the WHO S5: 25
 - frequency and significance of anemia in patients with 1109
 - high-dose therapy for (Review) S1: 9
 - pathology of various types S5: 45
 - primary therapy for (Clinical case) 95
 - tumor vaccination in combination with autologous stem cell transplantation (Review) S1: 41
- lymphoplasmacytoid lymphoma/immunocytoma
 - impact of HCV infection on clinical features, quality of life and survival of patients 499
- lymphocyte predominance
 - of Hodgkin's disease S5: 39
- lysolipids
 - in the peritoneal spread of ovarian cancer 437
- lysophosphatidic acid
 - in malignant effusions 437
- M**
- MABTHERA**
 - in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma 995
- malignancy
 - and rhEPO in the treatment of chemotherapy-induced anemia 255
- malignant lymphoma
 - classification (Commentary) 607
- malignant mesothelioma (Review) 139
- MALT lymphomas**
 - treatment and prognosis (Short report) 779
- mandible
 - pain as the leading clinical symptom for metastatic disease (Clinical case) 559
- mantle-cell lymphoma
 - chromosomal translocation t(11;14)(q13;q32) in 519
- marine natural products
 - against hematological and solid malignancies (Editorial) 937
- marrow transplant
 - in diffuse large-cell lymphoma (Review) S1: 23
- mass screening
 - for prostate cancer (Debate) 1279
- mastectomy
 - in neoadjuvant chemoendocrine therapy in primary breast cancer 1179
- MDR**
 - modulator S9788 used in patients with ventricular arrhythmia and torsade de pointe 1233
- MDR1 gene**
 - in primary human breast cancer 85
- media
 - in evidence-based health care (Review on evidence-based cancer medicine) 963
- mediastinum
 - in large B-cell lymphoma with sclerosis (Short report) 1027
- medical oncology
 - certification and training through the ESMO programme (Special article) 585
- medullary thyroid carcinoma
 - current diagnosis and management (Review) 695
- melanoma
 - from an occult primary lesion 419
 - model in mice 63
- MEN II**
 - in patients with medullary thyroid carcinoma (Review) 695
- mesothelioma
 - good symptom relief with palliative MVP chemotherapy 269
- meta-analysis
 - in the field of economy in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167
 - of reviews using individual patient data (Review on evidence-based cancer medicine) 827
 - of studies in clinical medicine (Review on evidence-based cancer medicine) 601, 703
- metastases
 - confined to the lungs of breast cancer patients 413
- metastatic breast cancer
 - bi-weekly paclitaxel as first-line treatment (Short report) 1247
 - treatment with paclitaxel, 5-fluorouracil and leucovorin 45
 - detection by ¹¹¹In-pentetreotide scan (Clinical case) 213
 - ifosfamide in association with vinorelbine in patients with (Short report) 565
- metastatic colorectal cancer
 - a phase II study of irinotecan, 5-fluorouracil and leucovorin in first-line chemotherapy 1199
- methadone
 - compared to morphine for the treatment of cancer pain 79
- methotrexate
 - as a treatment for patients with head and neck cancer (Short report) 225
- 5-methylhydrofolate
 - for biochemical modulation of fluorouracil in patients with advanced colorectal cancer 1309
- micromanipulation
 - in Hodgkin's disease S5: 17
- microsatellite shift
 - in patients with non-small-cell lung cancer (Short report) 113
- minimal disease
 - detection in blood or bone marrow 1269
- minimal residual disease
 - assessed by cytofluorometry and PCR in patients with chronic lymphocytic leukemia 167
 - in autologous hematopoietic harvests from breast cancer patients (Review) 821
 - in the immunotherapy for lymphoma (Review) S1: 31
- minor groove binding agents
 - against human tumors explanted from patients 981
- mixed cryoglobulinemia type II
 - pathogenesis of and associated with lymphoplasmacytoid lymphoma 495

- mobilization
 - of G-CSF and CTX in breast cancer patients (Short report) 913
- molecular
 - biology of breast cancer (Special article) 133
 - genetics of cancer and its recent advances (Commentary) 23
 - genetics of Hodgkin's lymphoma S5: 45
 - remissions in patients with chronic lymphocytic leukemia 167
- monoclonal antibodies
 - for treatment of patients with recurrent low-grade or follicular non-Hodgkin's lymphoma 995
 - in relapsed B-cell lymphoma 527
 - prognostic value of bone marrow involvement in small-cell lung cancer (Review) 247
 - staining of bone marrow aspirates in patients with small-cell lung cancer 181
- monitoring
 - hepatic dysfunction in liver disease by tamoxifen (Clinical case) 1123
- morphine
 - in association with somatostatin in advanced cancer patients with pain (Letter to the editor) 921
- mortality
 - from prostate cancer in Vaud and Neuchâtel, Switzerland 31
 - from prostate cancer reduced by PSA screening (Debate) 1293
- multidrug resistance
 - and P-glycoprotein expression in human neuroblastoma cells 1009
 - gene product in primary human breast cancer 85
- multimodality treatment
 - of oesophageal cancer (Review) 951
- multiple tumours
 - descriptive epidemiology of vulvar and vaginal cancers 1229
- multistep progression
 - in tumour types (Commentary) 23
- multivariate analysis
 - of clinical, haematological and immunological features 857
- mycosis fungoides
 - in patients with peripheral T-cell lymphoma (Short report) 1251
- myelosuppression
 - of cytotoxic drug therapy (Special article) 357
- myelotoxicity
 - in pretreated chronic lymphocytic leukaemia 721
- N**
- N2-disease
 - VSP as a suitable regimen 261
- nail disorders
 - induced by dose-intensified paclitaxel (Letter to the editor) 1139
- narrative reviews
 - in clinical medicine (Review on evidence-based cancer medicine) 601
- nasopharyngeal cancer
 - activity of paclitaxel by infusion in Asian patients (Short report) 327
- neoadjuvant chemotherapy
 - for locally advanced squamous-cell cervical cancer 977
 - in primary breast cancer 1179
- neoplasia
 - and the treatment of chylopericardium (Clinical case) 1339
- neoplasms
 - descriptive epidemiology in vaginal and vulvar cancers 1229
- nephrotic syndrome
 - in Hodgkin's disease S5: 109
- neuroblastoma
 - cells with the presence of classical multidrug resistance and P-glycoprotein expression 1009
- neurophysiology
 - and the use of neurotoxic drugs 443
- neurotoxicity
 - of carboplatin 443
- neutropenia
 - prospective evaluation of clinical models (Special article) 357
- nodular sclerosis
 - as a manifestation in Hodgkin's disease (Clinical case) 449
- non-Hodgkin's lymphoma
 - and CD4 lymphocyte deficiency in the antiphospholipid syndrome (Letter to the editor) 921
 - chemotherapy with MACOP-B in combination with involved field radiation therapy (Short report) 1027
 - classification published by the WHO S5: 25
 - epidemiology and the geographic locations of major subtypes 717
 - population-based results of treatment in elderly patients 1219
 - prophylactic treatment for central nervous system 191
 - treatment of grey zone lymphomas (Review) S5: 121
 - treatment with CNOP and r-hu-G-CSF (Short report) 1135
 - treatment with high-dose chemotherapy and hematopoietic stem cell transplantation (Review) S1: 1
 - treatment with lamivudine for fulminant reactivated hepatitis B infection (Rapid publication) 385
 - workshop on peripheral T-cell lymphomas (Commentary) 835
- non-small-cell lung cancer
 - a phase I-II study of paclitaxel, isofamide and vinorelbine with filgrastim (rhG-CSF) support (Short report) 677
 - a phase II study of 9-aminocamptothecin 1085
 - a pilot study of potential use of FDG-PET scan after induction chemotherapy 1193
 - detection of chromosome 3p alterations in serum DNA (Short report) 113
 - first-line treatment with docetaxel and cisplatin (Short report) 331
 - gemcitabine plus cisplatin regimen treatment (Short report) 457
 - salvage treatment with paclitaxel and gemcitabine after cisplatin- or docetaxel-based chemotherapy (Short report) 1127
 - treating stage IIIA (N2) (Editorial) 243
 - VIP induction chemotherapy 261
- nuclear medicine
 - for primary breast cancer presenting as metastatic carcinoma of unknown primary origin (Clinical case) 213
- numb lip syndrome
 - as a sign for metastatic disease (Clinical disease) 559
- O**
- occult
 - primary lesion of patients with visceral metastatic melanoma 419
- ocular adnexal lymphomas
 - treatment and prognosis (Short report) 779
- OEPA
 - used for the treatment of pediatric Hodgkin's disease (Review) S5: 115
- oesophageal cancer
 - treatment with multimodality therapy (Review) 951

- oncology
 - cost-effectiveness analysis (Review) 475
- onycholysis
 - in patients treated with docetaxel (Letter to the editor) 230
- opioid agonists
 - in cancer pain 79
- OPPA
 - used for the treatment of pediatric Hodgkin's disease (Review) S5: 115
- oral
 - antiemetic
 - the role of granisetron and dexamethasone in patients receiving highly emetogenic chemotherapy 661
 - chemotherapy
 - in a phase I clinical and pharmacokinetic study 1315
 - platinum analogue
 - in a phase I clinical and pharmacokinetic study 1315
- osteosarcoma
 - intensive multidrug chemotherapy and surgery 893
 - late peritoneal metastasis in a patient (Clinical case) 907
- outcome
 - assessment with PET after IC in N₂ non-small-cell lung cancer 1193
 - impact on clinical 55
 - of care for cancer patients (Review) 365
 - of questions regarding PSA screening (Debate) 1283
- ovarian cancer
 - accuracy of staging as an important prognostic determinant in stage I 1097
 - consolidation therapy (Letter to the editor) 229
 - DNA-topoisomerase I activity and content 313
 - efficacy and safety of the paclitaxel and carboplatin combination 37
 - LPA-like activity in the peritoneal spread 437
 - multiple changes in cisplatin-resistant cell lines 423
 - oxaliplatin in the treatment (Review) 1053
 - recommendations for medical management (Special article) 939
 - study of gemcitabine in platinum pre-treated patients (Short report) 1343
- overdiagnosis
 - of prostate carcinoma by screening (Debate) 1297
- oxaliplatin
 - in colorectal carcinoma patients (Short report) 105
 - in combination with high-dose leucovorin and 5-fluorouracil (Short report) 1251
 - in the treatment of advanced colorectal cancers (Review) 1053
 - in the treatment of metastatic colorectal cancer (Short report) 1251
- P**
- P-glycoprotein
 - activity in primary human breast cancer 85
 - expression in human neuroblastoma cells 1009
 - toxicity of S9788 in blocking concentrations for patients with ventricular arrhythmia and torsade de pointe 1233
- paclitaxel
 - activity in Asian patients with nasopharyngeal cancer (Short report) 327
 - clinical phase I study with one-hour infusion (Short report) 569
 - combined with cisplatin and ifosfamide in locally advanced squamous-cell cervical cancer 977
 - combined with 5-fluorouracil plus leucovorin in the treatment of metastatic breast cancer 45
 - combined with gemcitabine for patients with non-small-cell lung cancer (Short report) 1127
 - combined with gemcitabine in patients with refractory solid tumors 733
 - combined with ifosfamide and vinorelbine with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer (Short report) 677
 - hypersensitivity reactions (Letter to the editor) 573
 - in a first-line treatment in metastatic breast cancer (Short report) 1247
 - inducing multiple nail disorders (Letter to the editor) 1139
- pain
 - methadone and other agonists for the treatment of cancer patients 79
- palliative medicine and supportive care
 - as assessment of quality of life 1091
- paraneoplastic lesions
 - as paraneoplastic manifestation in Hodgkin's disease (Clinical case) 449
- pathology
 - and carboplatin toxic effects 443
 - in cases of Hodgkin's disease and related diseases S5: 31, 45
- patterns of care
 - in a population-based study on survival of small-cell lung cancer patients 543
- PB SCT
 - as a predictor of toxicity for patients with Hodgkin's disease 289
- PCR
 - the detection of identical Hodgkin-Reed Sternberg cell specific immunoglobulin gene rearrangements 283
- pegylated liposomal doxorubicin
 - for patients with Kaposi's sarcoma 711
- pericardial effusion
 - of chylous fluid in chylopericardium (Clinical case) 1339
- peripheral
 - blood stem cell transplantation
 - for patients with diffuse large-cell lymphoma (Review) S1: 9
 - neurotoxicity
 - evaluation and interpretation of the studies using different scales 739
 - T-cell lymphoma
 - as a developing concept (Editorial) 797
 - initial features, natural history and prognostic factors 849
 - report of the European Task Force (Commentary) 835
 - therapy with gemcitabine (Short report) 1351
- peritoneal metastasis
 - in a patient with osteosarcoma (Clinical case) 907
- PET scanning
 - in clinical oncology (Editorial) 353
 - in the detection of liver metastases 397
 - showing bilaterally mediastinal uptake in relation to seminoma and sarcoidosis (Letter to the editor) 924
- pharmacodynamics
 - in a phase I and pharmacologic study of DMP 840 (Short report) 101
- pharmacoeconomics
 - cost-effectiveness in oncology (Review) 475

- cost-effectiveness of interferon in chronic myeloid leukemia 389
- pharmacokinetics
- analysis of DMMP 840 (Short report) 101
 - for fluoropyrimidine-refractory colorectal cancer 173
 - of SN-38 and its glucuronide, depending on the genotypes of UGT1A1 (Rapid publication) 845
 - study of anti-CD20 monoclonal antibody in relapsed B-cell lymphoma 527
- phase I
- clinical and pharmacokinetic study of the oral platinum analogue JM216 1315
 - clinical trial
 - of *in vitro* tests predicting myelosuppression of cytotoxic drug (Special article) 357
 - of paclitaxel and gemcitabine in patients with refractory solid tumors 733
 - study
 - of DMP 840 administered by 24-hour infusion (Short report) 101
 - with one-hour paclitaxel infusion (Short report) 569
 - trial
 - of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors 1003
 - of novel anti-cancer agents (Special article) 1047
- phase II
- study of
 - a novel gemcitabine plus cisplatin regimen for non-small-cell lung cancer (Short report) 457
 - bimonthly leucovorin, 5-fluorouracil and oxaliplatin for metastatic colorectal cancer (Short report) 1251
 - gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer (Short report) 1343
 - treatment of advanced non-small-cell lung cancer with docetaxel and cisplatin (Short report) 331
 - high-dose topotecan with granulocyte-colony stimulating factor in fluoropyrimidine-refractory colorectal cancer 173
 - oral clofazimine in unresectable and metastatic hepatocellular carcinoma (Short report) 217
 - oxaliplatin in previously untreated colorectal carcinoma patients (Short report) 105
 - paclitaxel in combination with cisplatin in squamous cell carcinoma of head and neck (Short report) 335
 - vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 1103
 - trials
 - of cisplatin and gemcitabine in advanced squamous-cell carcinoma of head and neck (Short report) 1347
 - of Doxil (liposomal doxorubicin) (Short report) 1131
 - of non-small-cell lung cancer treated with paclitaxel and gemcitabine (Short report) 1127
 - in lung cancer (Editorial) 1045, 1079
 - of novel anti-cancer agents (Special article) 1047
- phase III
- study of the
 - impact of adding leucovorin to 5-fluorouracil in advanced colorectal carcinoma 535
 - role of pneumatic compression in the treatment of postmastectomy lymphedema 187
 - trial
 - comparing low-dose leucovorin and fluorouracil with high-dose fluorouracil for colorectal cancer 727
- pheochromocytoma
- in patients undergoing thyroidectomy for medullary thyroid carcinoma (Review) 695
- photodynamic therapy
- of malignant pleural mesothelioma (Review) 139
- physiopathology
- of a patient with osteosarcoma having late peritoneal metastasis (Clinical case) 907
- platinum
- in the treatment of advanced colorectal cancers (Review) 1053
- pneumatic compression
- in the treatment of postmastectomy lymphedema 187
- pneumocystis carinii*
- pneumonia in breast cancer (Letter to the editor) 573
- population-based registry
- of elderly patients with non-Hodgkin's lymphoma in the Netherlands 1219
- ports
- connected to a Groshong catheter used for long-term chemotherapy 767
- positive immunostaining
- in patients with small-cell lung cancer 181
- post-transplant lympho-proliferative disorder/disease
- in a child developing Hodgkin's disease (Short report) 673
 - linked to the Epstein-Barr virus S5: 5
- prediction model
- of hematological toxicity of cytotoxic drug (Special article) 357
- preferences
- of using anecdotal information in evidence-based health care (Review on evidence-based cancer medicine) 963
- prevention
- for patients with an observed reduction in breast cancer (Commentary) 973
- preventive care
- for patients with hereditary breast and ovarian cancer (Special article) 939
- primary
- breast cancer
 - prognostics of CD44v6 (Short report) 109
 - chemotherapy
 - as a better therapeutic option for patients with breast cancer (Editorial) 1151
 - metastases
 - in Ewing tumor 275
 - refractory
 - Hodgkin's disease S5: 97
- progenitor cells
- transplantation in acute myeloid leukemia in first complete remission 151
- prognosis in
- acute myeloid leukemia 159
 - blood or bone marrow tumor cells (Review) 1269
 - lymphocyte predominance Hodgkin's disease S5: 39
 - peripheral T-cell lymphomas 849
 - primary cervical malignant teratoma (Clinical case) 1015
 - Sézary syndrome 857
 - small-cell lung cancer (Review) 247

- stage I ovarian carcinoma 1097
- visceral metastatic melanoma 419
- prognostic factor
 - for salvage in Hodgkin's disease S5: 91
 - in diffuse large-cell lymphoma in first remission (Review) S1: 9
 - in intermediate grade and immunoblastic lymphoma 511
 - in primary breast cancer (Short report) 109
 - in Sézary syndrome 857
 - in non-Hodgkin's lymphoma patients with anemia 1109
- prognostic impact
 - of an activation of coagulation in lung cancer (Letter to the editor) 1255
- prolonged infusion
 - in patients with solid tumors 1003
- prophylactic treatment
 - of patients with aggressive non-Hodgkin's lymphoma 191
- prostate
 - overdiagnosis of carcinoma by screening (Debate) 1297
- prostate cancer
 - and the controversy of PSA screening (Debate) 1283, (Debate) 1293
 - incidence, mortality and survival in Vaud, Switzerland 31
 - screening or watchful waiting (Editorial) 9
 - screening with prostate specific antigen (PSA) 1263
- prostate specific antigen
 - screening for prostate cancer (Debate) 1279
 - testing as screening for prostate cancer (Editorial) 1263
- prostatic neoplasia
 - the use of PSA screening (Debate) 1279
- protein kinase C
 - related to the treatment of Hodgkin's lymphomas S5: 125
- proton density
 - of the amount of peritumoral edema in the brain 71
- pruritus
 - as a rare syndrome in Hodgkin's disease S5: 109
- PSA
 - screening for prostate cancer (Debate) 1293
- psoriasiform lesions
 - in Hodgkin's disease (Clinical case) 449
- psychometric validation
 - of a questionnaire (SELT-M) in patients with advanced cancer 1091
- publication bias
 - in clinical medicine (Review on evidence-based cancer medicine) 601, 703
- Q**
- quality
 - of life in patients with
 - breast cancer (Letter to the editor) 231
 - early breast cancer 745
 - Hodgkin's disease 297, S5: 147
 - localized prostate cancer 751
 - lymphoplasmacytoid lymphoma/immunocytoma 499
 - of life questionnaire for survivors (QLQ-S)
 - in Hodgkin's disease S5: 147
 - of studies in the field of cancer care (Review) 365
- quantitative PCR
 - for performing measurements of *bcl-2* mRNA in acute myeloid leukemia 159
- questionnaires
 - focussing on long-survival cancer patients 549
- R**
- radiation therapy
 - as a component of high dose salvage strategies in Hodgkin's disease S5: 87
 - in the treatment of malignant mesothelioma (Review) 139
- radiotherapy
 - added to adjuvant CMF chemotherapy (Commentary) 489
 - in early stage Hodgkin's disease S5: 57, 63
 - of primary extranodal lymphomas of the ocular adnexa (Short report) 779
- Raf-1
 - related to the treatment of Hodgkin's lymphomas S5: 125
- raloxifene
 - in combination with tamoxifen as a new treatment for breast cancer (Commentary) 973
- randomized
 - clinical trials investigating the role of moderate dose escalation in the treatment of advanced stage Hodgkin's disease S5: 73
 - concentration-controlled comparison of standard vs. prolonged infusions of etoposide phosphate in small-cell lung cancer 1205
 - controlled trials in cancer (Review on evidence-based cancer medicine) 483, 827
 - study of recombinant human erythropoietin in solid tumors 255
 - study of the role of pneumatic compression in the treatment of postmastectomy lymphedema 187
 - trial of weekly chemotherapy *versus* cyclical chemotherapy in the treatment of aggressive non-Hodgkin's lymphoma 633
 - trials of carboplatin *versus* cisplatin in solid tumors (Review) 13
- Ras
 - related to the treatment of Hodgkin's lymphomas S5: 125
- recombinant human erythropoietin
 - in the treatment of chemotherapy-induced anemia 255
- reduced toxicity
 - in patients with head and neck cancer 505
- Reed-Sternberg cell
 - in Hodgkin's disease S5: 17
- registry
 - of incidence, mortality and survival from prostate cancer 31
- relapse
 - of Hodgkin's disease S5: 91
- rate
 - after autologous stem-cell transportation for B-cell chronic lymphocytic leukemia or small lymphocytic lymphoma (Short report) 1023
- remission duration
 - caused by dose reduction of cladribine in pretreated chronic lymphocytic leukaemia 721
- reporting
 - randomized trials in cancer (Review on evidence-based cancer medicine) 483
- RER phenotype
 - of hereditary non-polyposis colorectal cancer 901
- residual mass
 - after primary therapy for lymphoma (Clinical case) 95
- resistance
 - of cell lines against cisplatin in patients with ovarian cancer 423

- response
 rate as an endpoint for cytotoxic agents in phase II trials of non-small-cell lung cancer 1079
 to novel anti-cancer agents (Special article) 1047
- RET mutation
 in patients with medullary thyroid carcinoma (Review) 695
- review literature
 on the field of treatment methods of malignant glioma (Review) 589
- rhodamine 123
 in primary human breast cancer multiparameter analysis 85
- risk factors
 in the addition of etoposide to CHOP chemotherapy in patients with high-grade non-Hodgkin's lymphoma 1213
- risk groups
 selecting staging procedures for the treatment of breast cancer patients (Arena) 1173
- rituxan
 in the treatment of patients with recurrent low-grade or follicular non-Hodgkin's lymphoma 995
- RNA-based methods
 in the detection of epithelial tumor cells in blood or bone marrow (Review) 1269
- RT-PCR
 performing quantitative measurements of *bcl-2* mRNA 159
- S**
- salvage chemotherapy
 for patients with
 germ cell cancer after failed high-dose therapy (Letter to the editor) 787
 head and neck cancer (Short report) 225
 Hodgkin's disease S5: 91
 Primary refractory Hodgkin's disease S5: 97
- salvage radiotherapy
 for patients with primary refractory Hodgkin's disease S5: 97
- sarcoidosis
 coincidence of seminoma (Clinical case) 321
- scheduling
 in the treatment with paclitaxel of patients with metastatic breast cancer (Short report) 1247
- screening
 for prostate cancer and the controversy of complying (Debate) 1283, (Debate) 1293
 for prostate cancer and the risk of overdiagnosis (Debate) 1297
 for prostate cancer with PSA (Editorial) 1263
 to prevent colorectal cancer through sigmoidoscopy 613
- secondary analysis
 in order to make health care decisions for cancer (Review on evidence-based cancer medicine) 1167
- secondary malignancies
 after therapy for Hodgkin's disease (Review) S5: 115
- second-line doxorubicin
 after high-dose ifosfamide in patients with advanced soft tissue sarcoma (Short report) 783
- selective cytoprotection
 with amifostine in concurrent radiotherapy for head and neck cancer 505
- seminoma
 and sarcoidosis (Letter to the editor) 924
 coincidence of sarcoidosis (Clinical case) 321
- sequelae
 in patients treated with brachytherapy and external beam irradiation for localized prostate cancer 751
- serum DNA
 chromosome 3p alterations in (Short report) 113
- Sézary syndrome
 prognostic factors and multivariate analysis of clinical, haematological and immunological features 857
- SF-36
 health survey in Italian long-survival cancer patients 549
- side effects
 of PSA screening for prostate cancer 1293
- single agent
 gemcitabine in patients with recurrent ovarian cancer (Short report) 1343
- single-cell PCR
 in Hodgkin's disease S5: 17
- skin involvement
 in peripheral T-cell lymphoma patients (Short report) 1351
- skin lesions
 in Hodgkin's disease (Clinical case) 449
- small-cell lung cancer
 bone marrow involvement affecting the prognosis of patients (Review) 247
 improvement and plateau in survival of patients 543
 organ transplantation (Letter to the editor) 339
 positive immunostaining with MluCI of bone marrow aspirate 181
 treatment with infusions of etoposide phosphate 1205
- small lymphocytic lymphoma
 high incidence of relapse after autologous stem-cell transplantation (Short report) 1023
- soft tissue sarcomas
 activity in poor prognosis soft tissue sarcomas (Short report) 1131
 activity of doxorubicin after high-dose ifosfamide in adult patients (Short report) 783
 phase II trial of first-line high-dose ifosfamide 871
 treatment with combined high-dose ifosfamide and doxorubicin 877
 treatment with high-dose ifosfamide plus adriamycin (Short report) 917
- solid tumours
 the role of erythropoietin in patients (Editorial) 239
- somatostatin
 in association with morphine in advanced cancer patients with pain (Letter to the editor) 921
- specialization
 on the processes and outcomes of care for cancer patients (Review) 365
- staging
 lung neoplasms with the use of FDG-PET 1193
 of breast cancer (Arena) 1173
 of Hodgkin's disease with FDG-PET 1117
 of the tumor grade in patients with ovarian carcinoma 1097
- STAT
 factors related to the treatment of Hodgkin's disease S5: 125
- statistical models
 for the BEACOPP regimen for advanced stage Hodgkin's disease S5: 73

- stem cell transplant
 - and high-dose therapy for early poor prognosis Hodgkin's disease in first remission S5: 83
- stem cell transplantation
 - from breast cancer patients (Review) 821
- stem cells
 - in breast cancer patients receiving chemotherapy and G-CSF or G-CSF alone (Short report) 913
- supportive care
 - in the treatment of postmastectomy lymphedema 187
- suramin
 - the anti-proliferative effect towards human breast cancer cell lines 205
- surgery
 - of patients with colorectal cancer liver metastasis (Arena) 967
 - of patients with primary cervical malignant teratoma with a rib metastasis (Clinical case) 1015
 - with photodynamic therapy or intracavitary chemotherapy in MM (Review) 139
- survival
 - benefit of low-dose leucovorin to monthly 5-fluorouracil in advanced colorectal carcinoma 535
 - of patients with
 - adult lymphoblastic lymphoma 619
 - Ewing tumor 275
 - primary extranodal lymphomas of the ocular adnexa (Short report) 779
 - prostate cancer 31
 - small-cell lung cancer 181, 543
 - visceral metastatic melanoma 419
 - vulvar and vaginal cancers 1229
- survivors
 - of Hodgkin's disease S5: 147
- symptom relief
 - with palliative MVP chemotherapy 269
- systematic reviews
 - of published evidence (Review on evidence-based cancer medicine) 703
 - on the treatment of cancer patients (Review) 365
 - using individual patient data (Review on evidence-based cancer medicine) 827
- T**
- T-cell
 - classification of leukemias and lymphomas published by the WHO S5: 25
 - immunity
 - from autologous peripheral stem cell transplantation (Review) S1: 41
- T2-weighted images
 - of the amount of peritumoral edema in the brain 71
- tamoxifen
 - added to adjuvant CMF chemotherapy (Commentary) 489
 - in combination with raloxifene (Commentary) 973
 - in liver disease as potential exacerbation of hepatic dysfunction (Clinical case) 1123
 - used in neoadjuvant chemoendocrine therapy in primary breast cancer 1179
- TARC
 - in immune escape mechanisms in Hodgkin's disease S5: 21
- teratoma
 - with a rib metastasis in an adult (Clinical case) 1015
- testicular
 - cancer
 - and the effect of chemotherapy *in situ* 657
 - thoracic metastasectomy 1185
 - teratoma
 - occurrence of Frey's syndrome after cisplatin-based chemotherapy (Letter to the editor) 118
- tetrahydroisoquinoline alkaloids
 - against human tumors explanted from patients 981
- TGF γ
 - in Hodgkin's disease immune escape mechanisms S5: 21
- Th2
 - response of the Reed-Sternberg cells in Hodgkin's disease S5: 21
- therapeutic index
 - of concomitant chemoradiotherapy for head and neck cancer (Editorial) 471
- therapy
 - for Sézary syndrome 857
- thoracic metastasectomies
 - for germ-cell tumours 1185
- thymus hyperplasia
 - as diagnosis for lymphoma 95
- time trends
 - in mortality from prostate cancer 31
 - in incidence, survival and risk of second neoplasms following vaginal and vulvar cancers 1229
- TIPS
 - treatment for patients with a liver disease (Clinical case) 1123
- topoisomerase I
 - in epithelial ovarian cancer 313
 - inhibitors 313
- topotecan
 - in fluoropyrimidine-refractory colorectal cancer 173
- toxicity
 - in conditioning regimens in patients with aggressive non-Hodgkin's lymphoma (Review) S1: 15
 - of drugs in BEACOPP chemotherapy for advanced Hodgkin's disease S5: 67
 - of novel anti-cancer agents (Special article) 1047
 - of paclitaxel (Short report) 569
- training programme
 - for medical oncology (Special article) 585
- transesophageal echocardiography
 - performance in patients with symptoms of systemic arterial embolism (Clinical case) 775
- transferability
 - of economic analysis to make health care decisions (Review on evidence-based cancer medicine) 1167
- transformed follicular lymphoma
 - high-dose therapy with autologous haematopoietic support in patients 865
- transforming growth factor- β
 - in the presence of tamoxifen with human breast cancer 205
- translocation t(11;14)
 - in mantle cell lymphomas 519
- transplantation
 - in immune escape mechanisms in Hodgkin's disease S5: 21

- in primary refractory Hodgkin's disease S5: 97
- of cells in breast cancer patients receiving chemotherapy plus G-CSF or G-CSF alone (Short report) 913
- treatment
 - of advanced non-small-cell lung cancer (Short report) 331
 - of chemotherapy-induced anemia 255
 - of Hodgkin's disease S5: 133
 - of Hodgkin's disease in childhood and adolescence (Review) S5: 115
 - of post-transplant lymphoproliferative disease (PTLD) (Letter to the editor) 339
 - of stage IIIA (N2) lung cancer (Editorial) 243
 - strategy for lymphocyte predominance Hodgkin's disease S5: 39
 - with
 - 5-fluorouracil and mitomycin-C (Letter to the editor) 230
 - docetaxel and cisplatin of patients with non-small-cell lung cancer (Short report) 331
 - G-CSF (filgrastim)-supported FEC polychemotherapy 403
 - lamivudine for fulminant reactivated hepatitis B infection (Rapid publication) 385
 - paclitaxel of patients with nasopharyngeal cancer 327
 - paclitaxel in combination with cisplatin in head and neck cancer (Short report) 335
 - palliative MVP chemotherapy 269
 - three cycles of ABVD and high-dose extended irradiation 195
 - vindesine-ifosfamide-platinum induction chemotherapy 261
 - weekly 24-hour 5-FU/leucovorin 45
- triazinemipiperidine
 - dose limiting toxicities in patients with ventricular arrhythmia and torsade de pointe 1233
- tumor growth kinetics
 - in patients with advanced stage Hodgkin's disease S5: 73
- tumor markers
 - in patients with small-cell lung cancer 181
 - the role of alpha-fetoprotein (AFP) (Clinical case) 667
- tumor vaccine
 - strategies in combination with autologous stem cell transportation (Review) S1: 41
- U
 - unknown primary carcinoma
 - detection by ¹¹¹In-pentetreotide scan 213
- V
 - vagina
 - descriptive epidemiology of cancers 1229
 - validation
 - of the CFU-GM assay (Special article) 357
 - veno-occlusive disease
 - of the liver induced by gemcitabine (Letter to the editor) 681
 - vinorelbine
 - as a treatment for patients with head and neck cancer (Short report) 225
 - in combination with ifosfamide
 - in combination with paclitaxel and ifosfamide with filgrastim (rhG-CSF) support in advanced non-small-cell lung cancer (Short report) 677
 - in patients with anthracycline-resistant metastatic breast cancer (Short report) 565
 - in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck 1103
 - in the treatment of Hodgkin's disease S5: 103
 - viral pathogenesis
 - in Hodgkin's disease S5: 5
 - vulva
 - descriptive epidemiology of cancers 1229
- W
 - workshop report
 - on Hodgkin's lymphoma and related diseases S5: 31
- W71
 - involvement in a Burkitt's lymphoma in a patient with Denys-Drash syndrome 627
- X
 - X-ray computed tomography
 - after induction chemotherapy in N₂ non-small-cell lung cancer 1193

Index of authors Volume 9 (1998)

A

Aapro MS 917
 Aaronson NK 739
 Abbruzzese JL 213, 1003
 Abele R 95
 Achterrath W 45
 Ageitos A 1339
 Agelidou M 331
 Ahrens S 275
 Akrivakis C 1139
 Akrivakis K 573
 Albarello L 901
 Albertini P 1351
 Alberto P 95
 Alby N 939
 Alderman E 711
 Aleri M 1262
 Alessandrini F 1173
 Alietti A 779
 Als C 1015
 Alvarez Vincent JJ 1347
 Alvaro T 1355
 Amadori D 255
 Amess JAL 865
 Anchisi S 95
 Anderson JR 717
 Anderson N 13, 573
 Ando Y 845
 Andrade Santiago J 1339
 André T 1251
 Andreoni B 767
 Andrieu J-M 195
 Androulakis N 331, 1127
 Ang PT 327
 Anker G 403
 Ansari RH 1035, 1085
 Antón A 783, 871
 Antón-Torres A 727
 Aparicio J 727
 Apolone G 549
 Apostolidis J 865
 Apostolopoulou F 331
 Appino A 857
 Aranda E 727
 Aravantinos G 1031
 Arends JW 109
 Armand J-P 255, 653, 1103
 Armitage JO 468, 717, 1023, S5: 133
 Arranz F 871
 Asai G 845
 Ascani L 922
 Ascani S 269, 673, 797
 Ashley SE 1179
 Asserianis E 230
 Asterling S 787

Astudillo J 113

Athanassiades A 1031
 Attal M S1: 5
 Attardo G 885
 Au E 327
 Audisio E 55
 Audisio RA 951
 Autier P 581
 Ayers D 1247
 Aylesworth C 733

B

Baas P 139
 Bacarani M 499
 Bacchi M 535, 877, 1091
 Bafaloukos D 1031
 Bailey NP 633
 Baker SD 101, 173
 Baldini L 779
 Bancher-Todesca D 230
 Bangerter M 1117
 Bardou V-J 619
 Bari A 71
 Barillari G 499
 Barnard DL 633
 Barneto I 727
 Barone C 1199
 Barozzi P 495
 Barrada M 230
 Barry MJ 1279
 Bastian G 1233
 Bastit Ph 1103
 Bauer D 673
 Bauer J 1233, 1315
 Bauknecht T 569
 Bazan C 71
 Beale P 118
 Behringer D 821
 Beijnen JH 437
 Bell D 1343
 Bellmunt J 871
 Belzile M 79
 Benavides M 105
 Bence-Bruckler I 995
 Bendandi M 1351
 Bengtsson N-O 403
 Benner S 1035
 Bennmarker H 403
 Berdel WE 1323
 Bergamaschi D 989
 Berger HM 1331
 Bergh J 403
 Bergmann L 159, 1117
 Berinstein NL 995
 Bernell P 1213

Bernengo MG 857
 Bernhard J 231, 1091
 Bernhardt W 821
 Bernier J 238, 1268
 Berry G 711
 Bertelli G 187
 Bertelsen K 1301
 Berthillon P 469
 Berthold F 1009
 Bertini M 55
 Bertolini F 913
 Bertoni F 779
 Bertoni G 779
 Bessell EM 633
 Betticher DC 721
 Bianchi M 922
 Bielack SS 893
 Bieling P 893
 Bierling P 453
 Bierman PJ 1023
 Biffi R 767
 Billingham M 711
 Binder M 230
 Bischoff H S5: 67
 Bishop MR 1023
 Bjorkholm E 1301
 Björkholm M 1213
 Blaise D 619
 Blini M 779
 Bodrogi I 639
 Boffi R 922
 Bokemeyer C 787
 Boman K 1301
 Bonardi R 1297
 Bonaventura A 639
 Bonazzi C 1097
 Bonetti A 423
 Boni C 105
 Borchmann P S5: 103
 Borner MM 535, 690, 1315
 Borowski A 519
 Borrás JL 1355
 Bos GMJ 191
 Bosch F 167, 849
 Botta GA 499
 Botto B 55
 Bouabdallah R 619
 Bouafia F 1109
 Boudillet J 1103
 Boylan M 205
 Boyle P 581, 1263
 Bozec L 453
 Braghetti A 796
 Brandariz A 1347
 Bratina G 1097

Bremond A 939
 Brenner MK S5: 129
 Bressoud A 877
 Brière J 195
 Brogini M 313
 Brohée D 921
 Browman GP 377
 Bruera E 79
 Brune D 751
 Brunet S 849
 Bryce C 1247
 Buchmann I 1117
 Buesa JM 783, 871
 Bugat R 1343
 Büntzel J 505
 Burdach S 275
 Burks K 173
 Burnelli R 673
 Burris H 71
 Burris III HA 733
 Bury T 397
 Buzdar AU 413
 Buzzf F 639

C

Cabanillas F 511
 Cagini L 1185
 Calvi R 55
 Calvo R 113
 Calzas J 457
 Campbell C 1247
 Campbell L 1343
 Campisi C 565
 Campo E 835
 Campos D 639
 Candoni A 499
 Canellos GP 297, S5: 91
 Canuti D 1173
 Capella C 901
 Capello D 55
 Cappelaere P 1103
 Cappello N 857
 Carbone A 55
 Carenini N 423
 Carlisle PS 307
 Carrato A 727
 Carreras E 167
 Cartei G 225
 Casado A 783, 871
 Casado V 1339
 Casassus P 195
 Casimiro C 1339
 Cassano R 1140
 Castagna S 313
 Castellano D 457, 1347
 Castiglione M 489, 535, 973, 1091
 Castrillo JM 849
 Catalá M 431
 Cauchie P 921
 Cavaletti G 443
 Cavalli F 7, S5: 109
 Cavanna L 495
 Cella DF 297
 Celsing F 1213
 Cerna C 885
 Cerny Th 721, 877, 1015, 1091, 1233
 Cervantes A 727
 Cervera E 350
 Cetto GL 181, 247
 Chak A 307
 Chambers S 385
 Chaney SG 1053
 Chang J 1179
 Chapman ALN S5: 5
 Chapman BA 385
 Chasen MR 217
 Chaudri HA 639
 Chauvergne J 1103
 Cherin E 297
 Chiari S 1097
 Child JA 633
 Christensen TB 657
 Ciatto S 1297
 Cid J 849
 Cifani S 549
 Cisneros A 1123
 Clark FL 385
 Clark G 981
 Clarke M 827
 Clavero-Fabri M-C 653
 Cleton FJ 1331
 Coates AS 419, 489, 973
 Cocorocchio E 913
 Cocquyt V 1243
 Codegoni AM 313
 Coebergh J-WW 543
 Cognetti F 1199
 Cognetti F 565
 Coiffier B 803, 1109, S1: 5
 Colleoni M 489, 951, 1140
 Colli E 989
 Colombi M 779
 Colombo N 977
 Colomer D 167
 Colonna P 195
 Conter V 673
 Conti PS 924
 Cook GJR 353
 Cooper GS 307
 Cooper MR 297
 Cornaggia M 901
 Corrado C 151
 Cortés-Funes H 105, 457, 1347
 Cosset J-M S5: 57
 Costa A 228
 Cote C 1199
 Couette J-E 751
 Coyle D 475

Craft A 275
 Crombet T 431
 Crommelin MA 543
 Cullen MH 633
 Curé H 37
 Cvitkovic E 453, 1053
 Czuczman M 995

D

Da Prada GA 913
 Dąbrowska A 63
 Daenen M 1355
 Dalesio O 437
 Dallavalle G 105
 Daugaard G 657
 Dauplat J 939
 Davidson K 885
 De Braud F 105, 767, 917
 De Conno F 79, 922
 De Gramont A 1251
 De Haes CJM 745
 De Jong J 1315
 De Koning HJ 1293
 De Leyn PR 261, 1193
 De Matteis A 857
 De Mulder PHM 321, 924
 De Pas T 917
 De Sanctis V 1027
 De Tribolet N 580, 589
 De Wolf F 1135
 Debat P 453
 Deconinck E S1: 5
 Deeks JJ 375, 703
 Degardin M 1103
 Del Favero A 811
 Del Mastro L 187, 461
 Delling G 893
 Delmer A 129
 Delsol G 835, S5: 31
 Delval L 921
 Demedts MG 261, 1355
 Deneffe GJ 261
 Desablens B 195
 Desmery P 151
 DeWolf-Peters C S5: 31
 D'Incalci M 313, 937, 1315
 Di Loreto C 499
 Diaz-Canton EA 413
 Diaz-Rubio E 105, 727
 Diebold J 835, S5: 25
 Diehl LF 297
 Diehl V 221, 283, 289, S5: 1, 39, 67, 73, 79, 103, 147
 Diéras V 37
 Diergarten K 335
 Dietrich PY 589
 Dignani C 151
 Dimopoulos A-M 331, 1031
 Dimopoulou I 1127

Dini D 187
 Dirix L 1199
 Dobbie M 681
 Dockhorn-Dworniczak B 275
 Domine M 1339
 Donato V 1027
 Donehower RC 101, 173
 Dong K 511
 Donovan JL 1289
 Doveil GC 857
 Doyen Ch SI: 5
 Drengler R 71
 Drinkard LC 647
 Drudi G 1173
 Drummond MW 385
 Ducreux M 653
 Dühmke E S5: 67
 Dulude H 1247
 Dumontet C 1109
 Dunn J 633
 Dunst J 275
 Dupont PJ 1193

E

Earle CC 475
 Eberhardt W 45
 Eckardt JR 71, 733
 Eckhardt SG 733, 981
 Eghbali H S5: 147
 Eisenhauer EA 1047
 Eisinger F 939
 Elewaut AE 1243
 Elisaf MS 449
 Elsner K 1117
 Engert A 289, S5: 1, 67, 79, 103
 Enkin MW 963
 Epler D 893
 Erba E 989
 Erikstein B 403
 Erler G 31
 Errante D 923
 Escudero P 783, 871
 Espié M 939
 Esteve J 167
 Estevez L 1339
 Evans WK 475
 Evers LM 1135

F

Fabbrica D 443
 Fabi A 565
 Faircloth G 981, 989
 Falasca E 499
 Falini B 797
 Fandi A 653
 Fandi L 653
 Fanin R 499
 Fargeot P 1103
 Farish J 633

Fassone F 653
 Fattori PP 1173
 Fazio N 917
 Feingold J 939
 Feleszko W 63
 Feller AC 835
 Felman P 1109
 Ferguson MK 647
 Fermé C S5: 147
 Fernandez de Sevilla A 849
 Fernández I 151
 Ferrari A 627
 Ferrari MG 495
 Fetscher S 821
 Fey MF 535, 568, 721
 Fiebig HH 1323
 Fiebiger W 1309
 Fields-Jones S 71
 Fierro MT 857
 Filez L 1199
 Filiberti A 549
 Filshie J 118
 Finizio M 101
 Finkle C 885
 Fisher RI S5: 121
 Fishkin PAS 1085
 Flath B 573, 1139
 Flechtner H S5: 147
 Fletcher J 633
 Floren LC 1123
 Foran JM 865
 Ford HT 1179
 Fornander T 403
 Forno G 187
 Forral K 733
 Fossati-Bellani F 627
 Fossati V 779
 Fountzilas G 1031
 Fra J 783
 Franceschi S 31
 François S 195
 Franklin J S5: 39, 67
 Fraternali-Orcioni G 607, 1351
 Frattola L 443
 Freilone R 55
 Frickhofen N 1117
 Friederich P 639
 Friedlander M 1343
 Fröhlich B 275
 Fröhlich D 505
 Fromont P 453
 Frye D 413
 Fuchs N 893
 Fumoleau P 1103
 Furlan D 901

G

Gaidano G 55
 Gambirasio F 627

Gamucci T 255
 Garcia AA 1131
 Garcia-Carbonero R 1347
 Garcia JC 1035
 Garcia-Conde J 727, 849
 Garcia del Muro J 783, 871
 Garrone O 187
 Garufi C 1199
 Gascoyne RD S5: 31
 Gastaut J-A 619
 Gaulard Ph 835, S1: 5
 Geertsens PF 657
 Geffen DB 1142
 Gelber RD 489, 973
 Gelmon KA 1045, 1247
 Genvresse I 573
 Geoffrois L 1103
 Georgii A S5: 31, 67
 Georgopoulou T 1127
 Georgoulas V 331, 1127
 Geraghty JG 951
 Gerard B 1233
 Geroyianni A 1127
 Gershanovich M 639
 Ghandour C 195
 Gharib H 695
 Gherlinzoni F 1351
 Ghielmini M 8, 357, 989
 Giardini R 627
 Gibelli N 913
 Giermasz A 63
 Giroux B 1233
 Gisselbrecht C 835, S1: 5, S1: 15
 Giuffrida D 695
 Glaser C 559
 Glatzel M 505
 Glunz A S5: 67
 Godwin J 827
 Goedhals L 661
 Golab J 63
 Goldblum R 71
 Goldhirsch A 489, 535, 767, 810, 917, 973, 1140
 Goldman JM 351
 Goldstone AH S1: 9, S5: 83
 Goldstraw P 1185
 Golomb HM 677, 1085
 Gomez L 885
 Gómez H 457
 Gómez-Martin C 457
 Gonzalez M 849
 González G 431
 González Y 431
 Gordon M 357
 Gozza A 187
 Graf N 893
 Gralla RJ 811
 Gravel D 1003
 Gray JE 101
 Green D 995

Green M 691
 Greenberg D 297
 Greiner TC 339
 Gridelli B 673
 Grieshaber CK 357
 Griesshammer M 1117
 Grieve RJ 633
 Grilli R 365
 Grillo-López AJ 995
 Grimfors G 1213
 Grochow LB 101, 173
 Groff L 79
 Gross TG 339
 Grote W 519
 Gruia G 1199
 Grunicke HH S5: 125
 Guastalla JP 37
 Gucalp R 307
 Gueli-Alletti D 977
 Guerra JA 457
 Guetty-Alberto M 95
 Guffanti A 779
 Guidi G 181
 Guilhot F 195
 Guillén G 431
 Gumä J 1355

H

Hadovsky G 71
 Haedicke C S5: 67
 Hafner M 1117
 Hagemeister FB 511
 Hagenbeek A 191
 Haioun C SI: 5
 Hammond L 71
 Hanauske A-R 335
 Hander T 71
 Hanselmann S 535
 Hansen HH 585
 Hansmann M-L S5: 17, 39
 Hanson J 79
 Haraf DJ 647
 Harder S 519
 Håring B 569
 Harnett P 1343
 Harousseau J-L 195
 Harris NL 835, S5: 25, 31, 45
 Harstrick A 45
 Hasenclever D S5: 67, 73
 Hatzidaki D 331, 1127
 Hauns B 569
 Häusler R 1015
 Håvard Loge J S5: 137
 Havik E 437
 Haward RA 1073
 Haynes RB 377
 Hebert MF 1123
 Hedlund A 1213
 Hegewisch-Becker S 85

Heimans JJ 739
 Heinrich B 335
 Heise U 893
 Hejna M 1309
 Helwig S 1091
 Henderson E 297
 Henry-Amar M 751, S5: 147
 Henschler R 821
 Heras P 331
 Hermann R S5: 67
 Hermans J 1219
 Hernández JC 431
 Herndon II JE 297
 Héron J-F 661, 751
 Herrmann R 229, 255, 535, 681, 877, 967
 Herzog M 335
 Heslop H S5: 129
 Hess U 721
 Heusser P 1091
 Hickish T 269, 1179
 Hidalgo M 457, 1347
 Higgins A 1205
 Hillen HFP 109
 Himmelmann A 1301
 Hinrichs SH 339
 Hitt R 1347
 Hoelzer D 159
 Hofer S 681
 Hoffman PhC 647, 677, 1085
 Hogberg Th 1301
 Holland JC 297
 Holmer L S5: 67
 Homerin M 105
 Hopman GD 1331
 Hoppe RT S5: 87
 Hornbuckle K 307
 Horning SJ S5: 97
 Hortobagyi GN 413, 1151
 Horvath G 1301
 Horwich A 1185
 Hösli P 589
 Hossfeld DK 85, 585
 Hsu Schmitz S-F 721
 Hubens G 907
 Humblet Y 1199
 Humerickhouse R 1035
 Hunt DL 377
 Hupperets PSGJ 109
 Hürny C 1091
 Hustinx R 397

I

Igarashi T 527
 Iggo R 462
 Infanti L 499
 Inselmann G 775
 Ionta MT 565
 Iop A 225
 Isaia A 225

Iwan-Osiecka A 63
 Izbicka E 885, 981

J

Jack A 633
 Jacobsen A 1301
 Jacquet N 397
 Jacquin JP 37
 Jadad AR 963
 Jaffe ES 835, S5: 25, 31
 Jahns R 775
 Jais J-P 195
 Jakóbisiak M 63
 Janiaud P 939
 Jansen RHL 109
 Janssen-Heijnen MLG 543
 Jeffrey M 639
 Jensen Hjermstad M S5: 137
 Jerusalem G 397
 Jimeno J 981, 989
 Joel S 1205
 Joly F 751
 Joos S 519
 Joosten-Achjanie SR 109
 Jordan VC 1123
 Joss RA 667
 Jost LM 51
 Josting A 289, S5: 147
 Jox A 283
 Judson I 118
 Jungi F 682
 Juni M 151
 Jürgens H 275, 893

K

Kaasa S S5: 137
 Kaca A 63
 Kadin ME S5: 31
 Kaern J 1301
 Kagami Y 527
 Kakolyris S 331, 1127
 Kalogera-Fountzila A 1031
 Kamataki T 845
 Kanzler H 283
 Karakas T 159
 Kátay I 289
 Kau R 335
 Kaufman SS 339
 Kayitalire L 1343
 Keating MJ 131
 Kellokumpu-Lehtinen P 403
 Kemmerich M 335
 Kempf RA 1131
 Kenn W 775
 Keramopoulos A 1031
 Kersten MJ 1135
 Kessinger A 1023, SI: 23
 Ketterer N 1109
 Khouri IF 131

- Kim EE 213
 Kinoshita T 527
 Kinser JA 1015
 Klaassen U 45
 Kleisbauer J-P 661
 Klepsch A 1085
 Klinkhamer PJJM 543
 Kluin-Nelemans JC 1219
 Kluin PM 1219
 Knobel H S5: 137
 Knöppel-Schwark S 221
 Kobayashi Y 527
 Köhne C-H 967
 Kollath JP 1023
 Körholz D 893
 Kornacker M 283
 Kornblith AB 297
 Kornek GV 1309
 Kosmidis P 1031
 Kotsakis A 1127
 Kotz R 893
 Kotzerke J 1117
 Kourousis C 331
 Kouroussis C 1127
 Krause S S5: 67
 Krauseneck P 232
 Krauss SA 677, 1085
 Kraynak MA 71, 733
 Kröger N 85
 Kubista E 230
 Kubota K 1079
 Kugler JW 1035
 Kumagai K 117
 Kuoppola T 1301
 Küppers R 283, S5: 17
 Kurowski Ch 1009
 Kurrer MO 51
 Kuttah LA 307
 Kuttann F 939
 Küttner K 505
 Kwak LW S1: 41
- L**
 La Targia ML 779
 La Vecchia C 31, 1229
 Labianca R 105, 365
 Lad TE 1085
 Laeng H 1015
 Laffer UTh 1150
 Lage A 431
 Lambert HE 229
 Lambrechts AC 1269
 Lancaster J 71
 Langnas AN 339
 Lanza A 913
 Lasek W 63
 Lassus M 639
 Lathan B 221, S5: 67
 Laubenbacher C 335
- Lawrence R 885, 981
 Lazarus HM 307
 Le Prisé P-Y 195
 Lebrun J-P 939
 Leduc B 37
 Lefranc J-P 939
 Leitha T 559
 Lejeune F 195, 694
 Lemevel A 195
 Lenaz L 45
 Lentjes EGWM 1331
 Lentz MA 1103
 Lenzi R 213
 Leone R 423
 Lepage E S1: 5
 Lerut TE 261
 Lesaunier F 751
 Levi F 31, 1229
 Lévi F 453
 Leyvraz S 535, 877, 1233
 Lianes P 457
 Liberati A 365
 Lievens YN 261
 Liliemark J 1213
 Lionetto R 187
 Lisa F 857
 Lissoni A 877, 977
 List M 1035
 Lister TA 865
 Lobo F 1339
 Loeffler M S5: 67, 73
 Lokich J 13, 573
 Long JEH 217
 Longo G 495
 Löning T 85
 Lopez A 849
 Lopez-Guillermo A 167, 849
 López-Cabrerizo MP 113
 López-Pousa A 783, 871
 López-Vega JM 727
 Lorenz M 967
 Louvet C 1251
 Lowe S 228
 Lubiniecki GM 101
 Lucianetti A 673
 Ludwig H 639
 Lüftner D 1139
 Lum B 711
 Lund B 1301
 Luppi M 495
 Lurie H 639
 Lynch M 205
- M**
 Maartense E 1219
 Machaj E 63
 MacLennan KA S5: 31
 Magagnoli M 1351
 Magnani I 423
- Maier-Lenz H 569
 Makris A 1179
 Malmström P 403
 Maloney D 995
 Mandelli F 1027
 Mangioni C 313, 977, 1097
 Mani S 1035
 Maraninchi D 619
 Marasca R 495
 Maraveyas A 239
 Marinello P 431
 Mariuzzi L 499
 Marosi C 559
 Marsolais C 885
 Martelli M 1027
 Martelli MP 1027
 Martin FJ 711
 Martin J 783
 Martin J 871
 Martinelli G 913
 Martinez Rolón J 151
 Martini N 243
 Mascia T 495
 Masi A 1173
 Masip C 1355
 Masotti A 181
 Massidda B 565
 Massimino M 627
 Massuti T 727
 Masters GA 677, 1085
 Matthews J 865
 Matthiesen P 519
 Mattmann S 667
 Mauch PM S5: 57
 Mauer AM 677
 Maurer R 51
 Maurer U 159
 Mauri S 767
 Mavromanolakis E 331
 May D 580
 Mayer RJ 297
 Mazza U 55
 Mazzotta A 1297
 McLaughlin P 511, 995
 Meerpohl HG 569
 Mellink WAM S5: 147
 Menendez D 871
 Mergenthaler HG 1139
 Merk K 1213
 Mertelsmann R 821
 Messori A 389
 Metzke S 519
 Michelassi F 1035
 Michelet M 151
 Middleton GW 269
 Miething CC 159
 Mignot L 37
 Miholic J 1309
 Milani M 607, 673

Milionis HJ 449
 Millán JM 1347
 Millward MJ 1343
 Milone G 151
 Minoia C 443, 1315
 Minozzi S 365
 Mirabal V 431
 Misset JL 453
 Moher D 483
 Mondini P 627
 Monfardini S 255
 Montalban C 849
 Montserrat E 167, 835, 849
 Monzó M 113
 Moog F 1117
 Moolenaar WH 437
 Moon T 511
 Morant R 535
 Morel P SI: 5
 Moreno JA 1343
 Morishima Y 527
 Morselli M 495
 Mosconi P 549
 Moullet I 1109
 Mouloupoulos LA 1250
 Mounier N SI: 15
 Mousseau M 37
 Moss K 569, 1323
 Muggia FM 924, 1131
 Muller MJ 739
 Müller-Hermelink HK S5: 25, 31
 Munzone E 917
 Murate T 527

N

Nackaerts KL 261, 1355
 Nagler A SI: 31
 Nakashima L 1247
 Narabayashi M 527
 Nash AG 1179
 Nasti G 923
 Neal DE 1289
 Neidhart-Berard E-M 1109
 Neri A 779
 Neri B 255
 Netter-Pinon J 255
 Neuenschwander H 120, 474
 Neumann K 45
 Neymark N 1167
 Ng CYC S5: 129
 Nicholson AG 1185
 Nicol SJ 733
 Nicolaides C 1031
 Nishiwaki Y 1079
 Nolé F 767, 917, 1140
 Noordijk EM 1219, S5: 63
 Norfolk D 633
 Norton A 269
 Norton AJ 865

Norum J 613
 Novelli M 857
 Novero D 55
 Nowrousian MR 255

O

O'Brien MER 269
 O'Byrne K 1205
 O'Higgins N 639
 O'Reilly S 101, 173, 1247
 Oberhoff C 255
 Oberholzer M 681
 Obermair A 230
 Obrist R 1043
 Ogura M 527
 Ohtsu T 527
 Oliveira J 1103
 Oliver RTD 787
 Olschewski 745
 Onsrud M 1301
 Orfeuvre H 37
 Orlando L 917, 1140
 Orsi F 767
 Orsucci L 55
 Orvieto E 1140
 Osanto S 1331
 Ösby E 1213
 Ossenkoppele GJ 739

P

Pagani O 535, 661, 1233, 1315
 Pajak TF 471
 Palestro G 55
 Palombi F 1027
 Pampallona S 989
 Panzini I 1173
 Paolicchi A 423
 Papadakis E 331, 1127
 Papadimitriou C 331, 1031, 1127
 Papaldo P 565
 Papamichael D 865, 1205
 Papi M 1173
 Parchment RE 357
 Pariso D 37
 Parker P 307
 Parsa-Parsi R S5: 1, 79
 Parvis G 55
 Pasini F 181, 247
 Pasini G 1173
 Pasquini E 1173
 Pastore C 55
 Pastorino U 1185
 Patek A 711
 Patriarca F 499
 Patton WN 385
 Pau FM 1027
 Paulus P 397
 Paulus U S5: 67
 Paulussen M 275

Pauwels P 321
 Pavanel F 181
 Pavletic ZS 932, 1023
 Pavlidis N 1031
 Pavlovsky S 151
 Paz-Ares L 457
 Peccatori F 913
 Pellegrino A 977
 Pelosi G 181, 247
 Peña M 1347
 Penson R 1205
 Pény J 751
 Perego P 423
 Pereira J 79
 Pernet FPPM 321
 Perotti C 913
 Perotti D 627
 Perry AR SI: 9
 Peruzzotti G 1140
 Pescarmona E 1027
 Pestalozzi B 535
 Peterson BA 297
 Petrides PE 1139
 Petry KU 255
 Pettengell R 239
 Pfreundschuh M S5: 67
 Philippou Pari C 45
 Piccart MJ 133, 461
 Pichert G 51
 Pichlmeier U 85
 Pieniaszek Jr HJ 101
 Pierotti MA 627
 Pierret J 939
 Pierson JL 1023
 Pifarré A 113
 Pileri SA 607, 673, 797, 1351
 Pipan C 499
 Plate KH 1155
 Plendl H 519
 Plunkett W 1003
 Poggi S 673
 Pojda Z 63
 Polselli A 1173
 Pont J 787
 Poppema S S5: 21, 31
 Posner MC 1035
 Possinger K 573, 1139
 Postma FR 437
 Postma TJ 739
 Potters M S5: 21
 Poveda A 783, 871
 Powles TJ 1179
 Pozzi S 767
 Pozzo C 1199
 Priest K 269
 Prinz B 1139
 Pruckmayer M 559
 Puglisi F 499
 Puistola U 1301

Pujade-Lauraine E 37

Q

Quaglino P 857

Quasthoff S 335

R

Raber MN 213, 1003

Raderer M 1309

Radice P 627

Ragaz J 1247

Rahman Z 413

Rajewsky K S5: 17

Ramaccioni V 673

Randimbison L 31, 1229

Ratain MJ 1085

Ratschiller D 721

Ravaioli A 1173

Raymond E 981, 1053, 1251

Rebmann U 255

Reichardt P 639

Reiss P 1135

Renard J 1315

Rendina EA 1027

Resegotti L 55

Reske SN 1117

Reyes F S1: 5

Reymann A 85

Ribera JM 849

Richardson P 711

Rickinson AB S5: 5

Rielly S 1247

Rigo P 397

Rinaldi DA 733

Rio B 129

Ripamonti C 79, 922

Ripoche V 1343

Robertshaw H 1205

Robertson C 1140

Robles L 1339

Robustelli della Cuna G 913

Rodenhuis S 437, 1269

Rodriguez-Diaz Pavón J 511

Rodriguez GI 733

Rodriguez MA 511

Rodriguez-Monge E 413

Rogato A 499

Rogers M 1131

Roggero E 519

Rohatiner AZS 865

Roila F 811

Rolland F 1103

Romaguera JE 511

Romanelli S 423

Romieu G 639

Ronchi A 1315

Rooney CM S5: 129

Rosell R 113

Rosenberg J 995

Roskrow MA S5: 129

Rösler H 1015

Ross P 229

Rota S 1097

Rothenberg ML 71, 733

Rougier P 653

Rovira M. 167

Rowinsky EK 101, 173, 885

Rubió J 1355

Rudd R 1205

Rüdiger T S5: 31

Rueffer U 289

Ruff P 217

Rüfner J-U S5: 67, 147

Ruggiata R 549

Rustin GJS 229

S

Sabattini E 607, 797

Sacco C 55

Saglio G 55

Saijo N 1079

Sainty D 619

Saka H 845

Sakai C 117

Salar A 849

Salata RA 307

Salles G 803, 1109

Salmaso F 499

Salmi T 1301

Salzer-Kuntschik M 893

Sammur PH 339

Samuels BL 677

Sánchez-Céspedes M 113

Sandvei R 1301

Sappino AP 589

Sarkany M 1233

Sartorius S 101

Sasaki M 1155

Sasaki Y 527, 1079

Sastre J 105, 727

Schaad R 1091

Schefer H 667

Scheistroen M 1301

Scheithauer W 1309

Schellong G S5: 115

Schiffer C 297

Schilling A 297

Schilsky RL 1035

Schipper RM 543

Schläpfer J 1233

Schlegelberger B 519, 835

Schmitter D 51

Schnell R S5: 103

Schouten HC 109

Schouwink H 139

Schrijvers D 907

Schröder FH 1293

Schulz KF 483

Schweigert M 1139

Schwonzen M 221

Sciortino DF 1035, 1085

Scovassi AI 313

Seeber S 45

Seitz R 1255

Sekine I 1079

Serreyn R 1243

Sessa C 357, 661, 877, 977, 989, 1233, 1315

Sextro M S5: 67

Shamash J 787

Sharma A 733

Sheldon TA 365

Shen D 995

Shenkier T 1247

Shimokata K 845

Shipp MA S1: 47

Shulman KL 1035

Sieber M S5: 67, 147

Siebert R 519

Sierra J 167

Silver RT 297

Silvestri F 499

Simmons AV 633

Simonsen E 1301

Siu LL 885

Skarlos D 1031

Slavin S S1: 31

Slevin M 1205

Smith IE 269

Smith T 413

Snijder S 1219

Sobol H 939

Somberg KA 1123

Somville J 907

Sorbe B 1301

Souglakos J 1127

Sparano J 307

Spataro V 23, 936

Späth-Schwalbe E 573

Spencer L 269

Spina M 923

Spyridonidis A 821

Stack C 633

Stahel RA 51

Staib F 85

Staib P 221

Stappert-Jahn U S5: 67

Starkhammar H 1199

Stein H S5: 31

Steinmetz HT 221

Stephens CD 733

Sternberg C 1044

Steward WP 1265

Stoklosa T 63

Stolte M 775

Stoppa A-M 619

Stoppa-Lyonnet D 939

Stroobants SG 1193

Strumberg D 45
 Stuart NSA 633
 Stupp R 1233
 Sugiura S 845
 Suzuki N S5: 129
 Svedmyr E 1213
 Svetec D 1283

T

Taamma A 1053
 Tabernero JM 727
 Taborelli M 901
 Takagi T 117
 Talbot D 1205
 Tamura T 1079
 Tan EH 327
 Tassinari D 1173
 Tavio M 923
 Te V-C 31
 Terzoli E 1199
 Tesch H 221, 289, S5: 39, 67, 79
 Theiss F 335
 Thieblemont C 1109
 Thigpen JT 933
 Thödtmann R 335
 Tholander B 1301
 Thomas A 1265
 Thompson IM 1283
 Thouvenin D 939
 Tibiletti MG 901
 Tichelli A 721
 Tidy VA 1179
 Tilly H S1: 5
 Timothy AR 353
 Tinazzi A 365
 Tirelli U 923
 Tjan-Heijnen VCG 321, 924
 Tobinai K 527
 Tobler A 721
 Todisco E 1027
 Tolcher A 1247
 Tomao S 565
 Tonato M 811
 Torelli G 495
 Torretta L 913
 Torri V 1097
 Torti F 711
 Tournigand C 1251
 Touroutoglou N 1003
 Tredici G 443
 Trépo C 469
 Trés A 727
 Tresca P 1103
 Tristant H 939
 Tropé C 1301
 Tschümperlin B 673
 Tubiana-Mathieu N 37, 255
 Tummarello D 181
 Tura S 1351

Tzannes S 331, 1127

U

Unger C 569, 1323
 Urbano-Ispizua A 167

V

Vaccher E 923
 Valencak J 1309
 Valenti C 495
 Valenti V 871
 Valero V 413, 1151
 Vallisa D 495
 Van Belle S 1243
 Van Bleyenbergh P 1355
 Van Cutsem E 1199
 Van Deijk WA 1219
 Van den Bent M 191
 Van den Berg AM S5: 21
 Van den Berg HW 205
 Van der Burg MEL 229
 Van der Holt B 191
 Van der Schueren E 261
 Van Glabbeke M 1103
 Van Oers MHJ 1135
 Van Oosterom A 907
 Van Putten WLJ 191
 Van Raemdonck DE 261
 Van Rensburg CEJ 217
 Van Schil P 907
 Van 't Veer LJ 1269
 Van Trappen Ph 1243
 Van Wegberg B 1091
 Vandelli L 495
 Vandevelde A 1355
 Vansteenkiste JF 261, 1193, 1355
 Vardakis N 1127
 Varette C 1343
 Vartianen J 1301
 Velagapudi R 1323
 Venook AP 1123
 Venturini M 187, 461
 Verbeken EK 1193
 Verdonck LF 191
 Verduyn TJ 1135
 Verlato G 181
 Vermorken JB 585, 739
 Verweij J 807
 Viale G 1140
 Vicente J 1339
 Vidili G 187
 Viens P 37
 Vijuk G 419
 Villalona-Calero MA 71, 733
 Villamor N 167
 Villing A-L 653
 Vincent P 37
 Visser L S5: 21
 Vitolo U 55

Vitvitski L 469

Vlachonicolis J 331
 Vlasveld LTh 321, 924
 Voigtmann R 255
 Vokes EE 471, 647, 677, 1035, 1085
 Voliotis D 221
 Volovics A 109
 Volpe D 357
 Volpe G 55
 Von Broen IM 1323
 Von der Maase H 657
 Von Hoff DD 71, 733, 885, 981,
 Von Kalle K S5: 67
 Von Rohr A 721
 Von Rohr E 1091
 Vose JM 1023, S1: 1
 Vossos A 331

W

Wagener DJTh 585
 Watine J 1255
 Watson S 677
 Weber B 37
 Weber BL 929
 Weber-Matthiesen K 519
 Weber W 535
 Weidmann E 159
 Weijl NI 1331
 Weil C 1315
 Weinell P 893
 Weinländer G 1309
 Weisenburger DD 717, 1023
 Weiss GR 733
 Weiss LE S5: 31
 Weiss RB 297
 Wernecke KD 1139
 Werner M 893
 Wernli M 721
 Westberg R 1301
 Westermann AM 437
 Westra A 907
 Weyler J 9
 White CA 995
 Wickramanayake PD 221, 289
 Widell S 1213
 Widmer L 51
 Wijermans PW 1219
 Wiklund T 403
 Wilke H 45
 Wilking N 403
 Williams CJH 375, 601
 Winkelmann W 275
 Winkler K 893
 Winner J 339
 Winnerlein-Trump E S5: 67
 Winter S 289
 Wipkink-Bakker A 1331
 Wittes RE 251
 Wobst A 951

Wolchok S 297

Wolf J 283, S5: 67, 79

Woodroffe CM 633

Wu CD 1023

Wulf G S5: 67

Wyka D 677

X

Xerri L 619

Y

Yoder O 251

Z

Zagożdżon R 63

Zagonel V 55

Zaja F 499

Zampino MG 917

Zander T 283

Zanetta G 977, 1097

Zaniboni A 105

Zappa M 1297

Zappala A 565

Zarba J 653

Zhang Y 519

Zibera C 913

Zinzani PL 1351

Zittoun R 129

Zoetmulder FAN 139

Zoubek A 275

Zucca E 519, 835

Zucchetti M 1315

Zuckerman E 297

Zühlke-Jenisch R 519

Zulian G 721

Zunino F 423

Zwierzina H 255